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Maine Center for Disease Control and Prevention (Maine CDC) has published an annual report 
on infectious diseases in Maine for the last 19 years. This report is prepared by the Division of 
Infectious Disease and is intended to provide an overview of notifiable infectious diseases of 
public health importance in Maine.   
 
We could not produce this report without the continued support of our healthcare and public 
health partners throughout the state. We greatly appreciate all of the laboratories, healthcare 
providers, childcare centers, school nurses, veterinarians and others who provide disease 
surveillance information. Considerable time is spent assisting Maine CDC with infectious 
disease investigations and disease control measures that affect Maine residents. Public health 
partners’ active and critical role in the infectious disease surveillance cycle informs statewide 
policies and programs that protect our residents from infectious disease through health 
promotion, disease prevention, and early detection, containment, and treatment.   
 
We appreciate and encourage your vigilance in the effort to protect the people of Maine through 
timely, complete, and accurate notifiable infectious disease reporting. It is through these 
collaborative efforts that we are able to respond to emerging infectious disease threats and 
prevent outbreaks.   
 
We hope you find this report useful as we all work to protect and promote the health of Maine’s 
residents. As always, we welcome your feedback on how we can provide more useful disease 
information to you, our partners.  
 
For more information on what, when, and how to report infectious diseases please see 
Appendix I (Notifiable Conditions List) of this report, visit our website at 
www.mainepublichealth.gov, or call 1-800-821-5821.      
  
 
 
 
 
 
Lori Wolanski, MPH 
Director, Division of Infectious Disease 
Maine Center for Disease Control and 
Prevention 
Stephen Sears, MD, MPH 
State Epidemiologist 
Maine Center for Disease Control and 
Prevention 
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2012 Infectious Disease Surveillance Highlights 
 
• Pertussis cases more than tripled in 2012 due to a statewide outbreak. The highest 
number of cases were reported in residents from Cumberland, Somerset, and York 
counties. 
• The first case of West Nile Virus encephalitis was diagnosed in 2012 in a Maine resident 
with no history of travel outside of Maine. 
• Active Tuberculosis cases nearly doubled with 17 cases reported in 2012, compared to 9 
in 2011. Tuberculosis was identified in both US and foreign born individuals.  
• Vibriosis cases doubled in 2012. A collaborative effort among Maine CDC programs, 
Department of Marine Resources and Department of Agriculture, Conservation and 
Forestry investigated cases with Maine seafood consumption.  
• Gonorrhea cases increased 68% from 2011. Over half of the cases were reported in 
Androscoggin and Cumberland counties. 
• Tickborne diseases continued to increase in 2012, with 1,111 cases of Lyme disease 
reported. Cases of anaplasmosis doubled from 2011, highlighting the importance of 
awareness and prevention efforts around tickborne diseases in Maine. 
• Sexually transmitted diseases continued to disproportionately affect young people with 
41% of gonorrhea and 71% of chlamydia cases reported in the 15-24 year age group. 
State sponsored testing programs targeted testing for females in this age group. 
• In 2012, a school aged unvaccinated child died of influenza A/H3. 
• Four cases of invasive group A streptococcus (GAS) were associated with intravenous 
use of bath salts; two of the four cases developed streptococcus toxic shock syndrome. 
• 91 animals tested positive for rabies in 2012 compared to 66 animals in 2011. The 
positive animals included 45 raccoons, 30 skunks, 5 foxes, 5 bats, 4 cats, 1 woodchuck 
and 1 dog (first rabid dog identified since 2003). Maine has not had a human case of 
rabies since 1937. 
• Eight cases of confirmed acute hepatitis C were reported to Maine CDC in 2012, 
compared to 12 cases in 2011. The numbers of newly reported cases of chronic 
hepatitis C infections increased from 1,184 in 2011 to 1,216 in 2012. 
• Despite reported cases of giardiasis decreasing for the past two years, the rate of 
giardiasis in Maine (12.7 per 100,000 persons) is twice the national rate (5.4 per 100,000 
persons). 
• Diseases associated with international travel (such as malaria and shigellosis) occurred 
in Maine residents in 2012. As international travel becomes more common and residents 
visit areas with endemic infectious diseases, there is a need to emphasize preventive 
strategies among travelers. 
• In the fall of 2012, Maine was involved in a national investigation due to the recall of drug 
products contaminated with fungus. No contaminated product was received in Maine, 
though some Maine residents received contaminated product in other states. 
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The History of Public Health Surveillance 
The responsibility of government to control and prevent disease dates back hundreds of years.  
Government responsibility was exercised during the epidemics of plague, syphilis, and smallpox 
in the Middle Ages to identify possible sources of disease, isolate infectious cases, and 
quarantine their contacts to prevent further spread of infection.  Illness was monitored, 
regulations were enacted to prevent pollution of streets and public water supplies, and 
instructions issued for appropriate methods of burial and food handling.  
 
Infectious disease surveillance in the United States began soon after the colonies were 
established.  In 1741, Rhode Island passed legislation requiring tavern keepers to report 
contagious disease among their patrons. Two years later, Rhode Island enacted legislation 
requiring the reporting of smallpox, yellow fever, and cholera. National disease surveillance 
began in 1850, when mortality statistics were first published by the federal government based 
on the decennial census.  The legal requirement to collect national morbidity data in the United 
States was initiated in 1878 when Congress authorized the US Public Health Service to collect 
reports of the occurrence of diseases that require quarantine including cholera, plague, 
smallpox, and yellow fever.   
 
In 1885, the Maine State Board of Health was created and consisted of six members appointed 
by the Governor.  Disease reporting for a select few diseases was conducted by the Maine 
Board of Health.  In 1917 the Board was replaced by the Maine Department of Health.  
 
Overview of Public Health Surveillance 
Seventy-one infectious diseases are reportable in Maine with 55 considered nationally 
reportable.  The list of reportable infectious diseases in Maine changes periodically. The last 
update was in 2008.  Diseases may be added to the list as new pathogens emerge or when a 
previously recognized pathogen becomes more important.  Some diseases may be removed 
from the list as their incidence or importance declines.  While modern advances in sanitation, 
personal hygiene and immunizations provide greater control and prevention of some diseases, 
other infectious diseases continue to thrive and still other yet-to-be-identified infectious disease 
entities are constantly emerging. Vaccine preventable disease are re-emerging in some parts of 
the world due to decreasing vaccination coverage among children.  
 
The Maine Department of Health and Human Services (DHHS) Center for Disease Control and 
Prevention (Maine CDC) works with healthcare providers and laboratorians to gather infectious 
disease information, analyze it, and provide reports in a timely manner. Surveillance data assist 
us in identifying events that require immediate public health action, such as disease outbreaks 
and emerging diseases; identifying populations at higher risk of infection; monitoring trends in 
the burden of disease; guiding the planning, implementation and evaluation of disease 
prevention and treatment programs; and informing public policy. 
  
The public health "patient" is the community, and information about community health can be 
useful to the clinician providing care to the individual.  Partnership between public health 
professionals, healthcare providers, and clinical laboratories is critical to assure accurate, 
representative and timely information for all.  
 
Disease Reporting in Maine  
Healthcare providers, medical laboratories, healthcare facilities, administrators, health officers, 
veterinarians and others are required to report notifiable diseases to the Maine CDC (Appendix 
I).  Diseases that require specific and immediate public health response or are possible 
indicators of bioterrorism are to be reported immediately by telephone.  The remainder of 
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notifiable conditions are to be reported within 24 or 48 hours of recognition or strong suspicion 
of disease. 
 
Disease reports may be made by electronic laboratory report (ELR), telephone or fax to the 
Maine CDC 24 hours a day, 7 days a week. The reporting numbers are toll free: telephone 1-
800-821-5821 and fax 1-800-293-7534.  An epidemiologist is on call 24 hours a day, 7 days a 
week to respond to infectious disease emergencies.  Disease reports may also be mailed to the 
Division of Infectious Disease, 286 Water Street, 8th Floor, 11 State House Station, Augusta, 
Maine 04333-0011.  Non-confidential reports or requests for consultation can be sent by email 
to disease.reporting@maine.gov.  
 
Infectious disease conditions reportable in Maine, the Rules for the Control of Notifiable 
Conditions and current information regarding infectious disease incidence in Maine are available 
on the Maine CDC website (http://www.maine.gov/dhhs/mecdc/infectious-disease/epi/disease-
reporting/index.shtml).  
 
The Maine Health and Environmental Testing Laboratory (HETL) tests for most reportable 
conditions. Certain organisms are required to be sent to HETL for confirmatory testing and the 
rules for isolate submission can be found on the notifiable conditions list. Information on the 
testing performed at HETL is available at www.mainepublichealth.gov/lab. 
 
Purpose of Report 
The Reportable Infectious Diseases in Maine 2012 Summary provides descriptive epidemiology 
of reportable infectious diseases in Maine and serves as a document of public health 
surveillance data. The report allows public health officials to comprehend the burden of 
reportable infectious diseases in Maine.  For example, surveillance data has demonstrated the 
spread of deer ticks and Lyme disease within Maine.   
 
Methods 
The data in this report are based on case definitions developed by the Council of State and 
Territorial Epidemiologists (CSTE) and adopted by federal CDC and the Maine CDC. Case 
definitions may change from year to year. The case definitions used to classify 2012 data are 
available at http://www.cdc.gov/osels/ph_surveillance/nndss/PHS/infdis2011.htm. Cases 
meeting the confirmed or probable case definitions are presented in the annual report.  
 
Tables in the introduction section include all confirmed and probable cases reported to the 
federal CDC for their publications, unless otherwise noted.  Rates are calculated by dividing the 
number of cases by the appropriate population from the yearly U.S. Census estimates and 
multiplying by 100,000. Charts and graphs may not include the total number of cases due to 
missing information on patient characteristics, such as county of residence, symptom onset 
date, age and gender. 
 
Over time additional information may necessitate review and updates of historical data. The 
most current published report will have the updated historical counts and trends for all diseases. 
 
More detailed information about each disease condition, including educational materials for 
healthcare providers and the general public, is available at www.mainepublichealth.gov. 
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Counts of Selected Reportable Disease by Year, Maine, 2003 – 2012* 
 
Disease 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Anaplasmosis (HGE) 1 1 5 10 9 17 15 17 26 52 
Babesiosis 3 5 11 9 11 11 3 5 9 10 
Campylobacteriosis 146 141 159 137 149 151 171 148 195 189 
Chlamydia 2040  2120 2253 2304 2543 2594 2443 2586 3094 3413 
Cryptosporidiosis 20 22 30 52 56 46 67 93 51 58 
Dengue Fever NR NR NR NR NR NR 3 6 0 0 
Ehrlichia chaffeensis (HME) 0 0 1 4 3 1 1 4 1 3 
Giardiasis 184 155 202 192 197 188 223 223 171 169 
Gonorrhea 231  214 142 137 118 96 143 162 272 456 
Group A Streptococcal 
Disease (invasive) 
28 16 14 19 28 28 21 47 43 37 
Group B Streptococcal 
Disease, Infant (invasive) 
2 1 3 1 1 6 2 8 2 5 
H. Influenzae (invasive) 6 15 12 21 13 21 21 13 26 23 
Hemolytic uremic syndrome  0 2 0 6 1 1 2 1 2 2 
Hepatitis A, acute 16 16 9 8 5 18 1 7 6 9 
Hepatitis B, acute 7 11 14 26 19 15 15 13 8 9 
Hepatitis B, chronic NA NA NA NA 139 142 126 101 105 105 
Hepatitis C, acute 2 0 0 2 1 3 2 2 12 8 
HIV Infection 65  46 59 62 64 46 56 59 54 48 
Legionellosis 2 1 7 11 9 11 10 12 18 18 
Listeriosis 6 8 3 6 5 5 4 1 4 5 
Lyme disease 175 224 245 338 530 909 976 751 1012 1111 
Malaria 5 6 5 4 8 1 2 6 6 5 
Meningococcal disease 10 12 2 9 8 6 4 5 5 3 
MRSA, invasive NR NR NR NR NR 47 121 90 121 116 
Mumps 0 0 2 0 24 5 6 2 2 0 
Pertussis 91 195 55 174 83 49 80 53 205 737 
Q Fever 2 0 2 4 7 0 0 0 2 0 
Rabies, animal 82 69 61 127 86 70 63 67 66 91 
Salmonellosis 141 108 163 161 138 159 121 133 134 161 
Shiga toxin producing E. coli 15 18 29 49 41 26 19 21 28 20 
Shigellosis 7 13 15 10 14 20 5 8 32 7 
Streptococcus pneumoniae, 
invasive 
NA NA NA NA NA NA NA 151 136 102 
Streptococcus pneumoniae 
(drug resistant invasive) 
0 4 8 12 13 18 23 30 32 20 
Streptococcal Toxic Shock 
Syndrome 
1 1 0 0 1 0 0 21 12 10 
Syphilis (early) 15  2 3 16 14 20 14 39 20 19 
Tuberculosis 24  20 17 16 19 9 9 8 9 17 
Varicella (Chickenpox) 1012 363 318 238 366 269 235 247 226 258 
Vibriosis 3 4 2 5 0 3 4 5 4 10 
*Counts may change from year to year. 
NR = not reportable; NA = not available 
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Rates of Selected Reportable Disease by Year, Maine, 2003 – 2012* 
Disease 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Anaplasmosis (HGE) 0.1 0.1 0.4 0.8 0.7 1.3 1.1 1.3 2.0 3.9 
Babesiosis 0.2 0.4 0.8 0.7 0.8 0.8 0.2 0.4 0.7 0.8 
Campylobacteriosis 11.2 10.7 12.1 10.4 11.3 11.5 13.0 11.3 14.7 14.2 
Chlamydia 156.1 161.4 170.9 174.3 192.9 197.0 185.3 197.0 233.0 256.8 
Cryptosporidiosis 1.5 1.7 2.3 3.9 4.3 3.5 5.1 7.1 3.8 4.4 
Dengue Fever NR NR NR NR NR NR 0.2 0.5 0.0 0.0 
Ehrlichia chaffeensis (HME) 0.0 0.0 0.0 0.3 0.2 0.1 0.1 0.3 0.1 0.2 
Giardiasis 14.1 11.8 15.3 14.5 15.0 14.3 16.9 17.0 12.9 12.7 
Gonorrhea 17.7 16.3 10.8 10.4 9.0 7.3 10.9 12.3 20.5 34.3 
Group A Streptococcal 
Disease (invasive) 
2.1 1.2 1.1 1.4 2.1 2.1 1.6 3.6 3.2 2.8 
H. Influenzae (invasive) 0.5 1.1 0.9 1.6 1.0 1.6 1.6 1.0 2.0 1.7 
Hemolytic uremic syndrome  0.0 0.2 0.0 0.5 0.1 0.1 0.2 0.1 0.2 0.2 
Hepatitis A, acute 1.2 1.2 0.7 0.6 0.4 1.4 0.1 0.5 0.5 0.7 
Hepatitis B, acute 0.5 0.8 1.1 2.0 1.4 1.1 1.1 1.0 0.6 0.7 
Hepatitis B, chronic NA NA NA NA 10.6 10.8 9.6 7.7 7.9 7.9 
Hepatitis C, acute 0.2 0.0 0.0 0.2 0.1 0.2 0.2 0.2 0.9 0.6 
HIV Infection 4.2 3.5 4.4 4.3 3.9 3.5 4.3 4.3 4.1 3.6 
Legionellosis 0.2 0.1 0.5 0.8 0.7 0.8 0.8 0.9 1.4 1.4 
Listeriosis 0.5 0.6 0.2 0.5 0.4 0.4 0.3 0.1 0.3 0.4 
Lyme disease 13.4 17.1 18.6 25.6 40.2 69.1 74.0 57.2 76.2 83.6 
Malaria 0.4 0.5 0.4 0.3 0.6 0.1 0.2 0.5 0.5 0.4 
Meningococcal disease 0.1 0.9 0.2 0.7 0.6 0.5 0.3 0.4 0.4 0.2 
MRSA, invasive NR NR NR NR NR 3.6 9.1 6.9 9.1 8.7 
Mumps 0.0 0.0 0.2 0.0 1.8 0.4 0.5 0.2 0.2 0.0 
Pertussis 7.0 14.8 4.2 13.2 6.3 3.7 6.1 4.0 15.4 55.5 
Rabies, animal NA NA NA NA NA NA NA NA NA NA 
Salmonellosis 10.8 8.2 12.4 12.2 10.5 12.1 9.2 10.1 10.1 12.1 
Shiga toxin producing E. coli 1.2 1.4 2.2 3.7 3.1 2.0 1.4 1.6 2.1 1.5 
Shigellosis 0.5 1.0 1.1 0.8 1.1 1.5 0.4 0.6 2.4 0.5 
Streptococcus pneumoniae, 
invasive 
NA NA NA NA NA NA NA 9.9 10.2 7.7 
Streptococcus pneumoniae 
(drug resistant invasive) 
0.0 0.3 0.6 0.9 
 
1.0 1.4 1.7 2.3 2.4 1.5 
Syphilis (early) 1.2 0.2 0.2 1.2 0.7 1.5 1.1 2.9 1.5 1.4 
Tuberculosis 1.8 1.5 1.3 1.2 1.4 0.7 0.7 0.6 0.7 1.3 
Varicella (Chickenpox) 77.4 27.6 24.1 18.0 27.8 20.4 17.8 18.8 17.0 19.4 
Vibriosis 0.2 0.3 0.2 0.4 0.0 0.2 0.3 0.4 0.3 0.8 
*Counts may change from year to year. 
NR = not reportable 
NA = not available
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Reportable Diseases with Historically Small Numbers of Cases, Maine, 2003 - 2012 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 10 year total 
Anthrax 0 0 0 0 0 0 0 0 0 0 0 
Botulism, foodborne 0 1 0 0 0 0 0 0 0 0 1 
Brucellosis 0 0 0 0 0 0 0 2 0 0 2 
Creutzfeld-Jacob disease (<55 yo) 0 0 0 0 0 0 1 0 0 0 1 
Cyclosporiasis 0 1 0 0 0 0 0 1 0 0 2 
Diphtheria 0 0 0 0 0 0 0 0 0 0 0 
Encephalitis, Arboviral 0 1 0 0 0 0 0 0 0 0 1 
Hantavirus Pulmonary Syndrome 0 0 0 0 0 0 0 0 1 0 1 
Measles 0 0 0 0 0 0 0 0 0 0 0 
Plague 0 0 0 0 0 0 0 0 0 0 0 
Psittacosis 0 1 0 0 0 0 0 0 0 0 1 
Poliomyelitis 0 0 0 0 0 0 0 0 0 0 0 
Rubella 0 0 0 0 0 0 0 0 0 0 0 
Rocky Mountain Spotted Fever^ NR NR NR NR NR 1 5 2 1 3 12 
Severe Acute Respiratory 
Syndrome (SARS) 0 0 0 0 0 0 0 0 0 0 0 
Smallpox 0 0 0 0 0 0 0 0 0 0 0 
Tetanus 0 0 0 0 0 0 0 0 0 0 0 
Toxoplasmosis 0 1 0 0 0 0 0 0 0 0 1 
Trichinosis 0 0 0 0 0 0 0 1 1 0 2 
Tularemia 0 0 0 0 0 0 0 0 0 0 0 
Typhoid Fever 0 0 0 1 0 0 0 2 0 0 3 
Venezuelan Equine Encephalitis 0 0 0 0 0 0 0 0 0 0 0 
West Nile Virus  0 0 0 0 0 0 0 0 0 1 1 
Yellow Fever NR 0 0 0 0 0 0 0 0 0 0 
NR=Not reportable, ^Reported cases were probable only in 2012 
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2012
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Note:  Data are final as of 6/3/13.  
Pertussis (YTD only), Lyme Disease and Chlamydia numbers need to be multiplied by 10. 
 
2012 
YTD 
5-year 
median 
YTD 
 
Anaplasmosis 52 17 
Group A Strep, invasive 37 28 
 
Hepatitis A 9 6 
 
 
Hepatitis B, acute 9 15 
 
Legionellosis 18 11 
 
Meningococcal disease 3 5 
 
Shiga toxin E. coli (STEC) 20 26 
 
Shigellosis 7 14 
 
Syphilis 19 19 
 
Tuberculosis 17 9 
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Reportable Conditions, Number of Confirmed and Probable Cases and Rate per 100,000 Persons by County, Maine, 2012 
 Anaplasmosis Babesiosis Campylobacteriosis Cryptosporidiosis Ehrlichia 
chaffeensis 
Giardiasis 
County No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate 
Androscoggin 1 0.9 0 0.0 16 14.9 1 0.9 0 0.0 17 15.8 
Aroostook 0 0.0 0 0.0 7 9.9 5 7.1 0 0.0 6 8.5 
Cumberland 10 3.5 3 1.1 43 15.1 8 2.8 0 0.0 50 17.6 
Franklin 0 0.0 0 0.0 1 8.0 0 0.0 0 0.0 3 9.8 
Hancock 2 3.7 0 0.0 5 9.2 1 1.8 0 0.0 8 14.7 
Kennebec 2 1.6 1 0.8 19 15.6 11 9.0 0 0.0 19 15.6 
Knox 9 22.7 2 5.0 1 2.5 0 0.0 0 0.0 3 7.6 
Lincoln 9 26.3 0 0.0 8 23.4 2 5.9 1 2.9 7 20.5 
Oxford 0 0.0 0 0.0 9 15.7 1 0.0 0 0.0 7 12.2 
Penobscot 1 0.7 1 0.7 27 17.6 11 7.2 0 0.0 10 6.5 
Piscataquis 0 0.0 0 0.0 4 23.1 4 23.1 0 0.0 4 23.1 
Sagadahoc 0 0.0 0 0.0 5 14.2 1 2.8 1 2.8 5 14.2 
Somerset 1 1.9 0 0.0 8 15.4 6 11.6 0 0.0 11 21.2 
Waldo 0 0.0 0 0.0 4 10.3 3 7.7 0 0.0 3 7.7 
Washington 1 3.1 0 0.0 5 15.4 1 0.0 0 0.0 2 6.2 
York 16 8.0 3 1.5 27 13.6 3 1.5 1 0.5 14 7.0 
Maine Total 52 3.9 10 0.8 189 14.2 58 4.4 3 0.2 169 12.7 
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Reportable Conditions, Number of Confirmed and Probable Cases and Rate per 100,000 Persons by County, Maine, 2012 
 Haemophilus 
influenzae, invasive 
Hemolytic uremic 
syndrome 
Hepatitis A Hepatitis B, acute Hepatitis B, 
chronic 
Legionellosis 
County No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate 
Androscoggin 5 4.6 0 0.0 1 0.9 0 0.0 13 12.1 2 1.9 
Aroostook 1 1.4 0 0.0 0 0.0 1 1.4 2 2.8 1 1.4 
Cumberland 6 2.1 2 0.7 5 1.8 3 1.1 54 19.0 2 0.7 
Franklin 0 0.0 0 0.0 0 0.0 0 0.0 1 3.3 1 3.3 
Hancock 1 1.8 0 0.0 0 0.0 1 1.8 5 9.2 2 3.7 
Kennebec 2 1.6 0 0.0 1 0.8 0 0.0 4 3.3 2 1.6 
Knox 1 2.5 0 0.0 0 0.0 0 0.0 2 5.0 2 5.0 
Lincoln 1 2.9 0 0.0 0 0.0 0 0.0 1 2.9 0 0.0 
Oxford 0 0.0 0 0.0 1 1.7 0 0.0 0 0.0 1 1.7 
Penobscot 1 0.7 0 0.0 0 0.0 1 0.7 7 4.6 2 1.3 
Piscataquis 0 0.0 0 0.0 0 0.0 1 5.8 0 0.0 0 0.0 
Sagadahoc 1 2.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Somerset 0 0.0 0 0.0 0 0.0 0 0.0 3 5.8 2 3.9 
Waldo 0 0.0 0 0.0 0 0.0 1 2.6 1 2.6 0 0.0 
Washington 1 3.1 0 0.0 0 0.0 0 0.0 1 3.1 1 3.1 
York 3 1.5 0 0.0 1 0.5 1 0.5 11 5.5 0 0.0 
Maine Total 23 1.7 2 0.2 9 0.7 9 0.7 105 7.9 18 1.4 
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Reportable Conditions, Number of Confirmed and Probable Cases and Rate per 100,000 Persons by County, Maine, 2012 
 Listeriosis Lyme Disease Malaria Meningococcal 
invasive disease 
MRSA, invasive Mumps 
County No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate 
Androscoggin 0 0.0 80 74.3 0 0.0 1 0.9 4 3.7 0 0.0 
Aroostook 1 1.4 1 1.4 0 0.0 0 0.0 18 25.4 0 0.0 
Cumberland 0 0.0 266 93.7 4 1.4 1 0.4 31 10.9 0 0.0 
Franklin 0 0.0 6 19.6 0 0.0 0 0.0 2 6.5 0 0.0 
Hancock 0 0.0 59 108.1 0 0.0 0 0.0 2 3.7 0 0.0 
Kennebec 1 0.8 128 105.0 0 0.0 0 0.0 13 10.7 0 0.0 
Knox 0 0.0 109 274.8 0 0.0 0 0.0 2 5.0 0 0.0 
Lincoln 0 0.0 65 190.2 0 0.0 0 0.0 3 8.8 0 0.0 
Oxford 1 1.7 25 43.5 0 0.0 0 0.0 5 8.7 0 0.0 
Penobscot 0 0.0 21 13.7 0 0.0 0 0.0 11 7.2 0 0.0 
Piscataquis 0 0.0 2 11.6 0 0.0 0 0.0 3 17.4 0 0.0 
Sagadahoc 0 0.0 59 167.7 0 0.0 0 0.0 2 5.7 0 0.0 
Somerset 0 0.0 11 21.2 0 0.0 0 0.0 6 11.6 0 0.0 
Waldo 0 0.0 55 141.7 1 2.6 0 0.0 4 10.3 0 0.0 
Washington 0 0.0 7 21.6 0 0.0 0 0.0 2 6.2 0 0.0 
York 2 1.0 217 109.0 0 0.0 1 0.5 8 4.0 0 0.0 
Maine Total 5 0.4 1111 83.6 5 0.4 3 0.2 116 8.7 0 0.0 
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Reportable Conditions, Number of Confirmed and Probable Cases and Rate per 100,000 Persons by County, Maine, 2012 
 Pertussis Rabies, animal Salmonellosis Shiga toxin 
producing E. coli 
Shigellosis 
County No. Rate No. Rate No. Rate No. Rate No. No. 
Androscoggin 65 60.4 4  8 7.4 0 0.0 1 0.0 
Aroostook 5 7.1 0  4 5.6 0 0.0 0 0.0 
Cumberland 225 79.2 10  34 12.0 7 2.5 4 1.4 
Franklin 1 3.3 3  9 29.4 0 0.0 0 0.0 
Hancock 44 80.6 0  8 14.7 1 1.8 0 0.0 
Kennebec 64 52.5 14  25 20.5 4 3.3 0 0.0 
Knox 14 35.3 8  3 7.6 0 0.0 0 0.0 
Lincoln 2 5.9 4  2 5.9 0 0.0 0 0.0 
Oxford 31 53.9 7  5 8.7 0 0.0 0 0.0 
Penobscot 67 43.6 13  12 7.8 2 1.3 0 0.0 
Piscataquis 24 138.8 2  0 0.0 0 0.0 0 0.0 
Sagadahoc 12 34.1 7  2 5.7 0 0.0 0 0.0 
Somerset 102 196.5 1  7 13.5 0 0.0 0 0.0 
Waldo 9 23.2 7  2 5.2 0 0.0 0 0.0 
Washington 2 6.2 0  6 18.5 1 3.1 0 0.0 
York 70 35.2 11  34 17.1 5 2.5 2 1.0 
Maine Total 737 55.5 91  161 12.1 20 1.5 7 0.5 
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Reportable Conditions, Number of Confirmed and Probable Cases and Rate per 100,000 Persons by County, Maine, 2012 
 Streptococcus, 
invasive Group A 
Streptococcus 
pneumoniae, invasive 
Tuberculosis Varicella 
(Chickenpox) 
Vibriosis 
County No. Rate No. Rate No. Rate No. Rate No. Rate 
Androscoggin 4 3.7 14 13.0 3 2.8 8 7.4 0 0.0 
Aroostook 2 2.8 9 12.7 1 1.4 10 14.1 0 0.0 
Cumberland 6 2.1 17 6.0 10 3.5 66 23.2 6 2.1 
Franklin 2 6.5 1 3.3 0 0.0 5 16.3 0 0.0 
Hancock 0 0.0 3 5.5 1 1.8 11 20.2 0 0.0 
Kennebec 9 7.4 16 13.1 0 0.0 26 21.3 0 0.0 
Knox 1 2.5 1 2.5 0 0.0 9 22.7 0 0.0 
Lincoln 1 2.9 5 14.6 0 0.0 7 20.5 0 0.0 
Oxford 0 0.0 2 3.5 0 0.0 8 13.9 0 0.0 
Penobscot 7 4.6 20 13.0 0 0.0 24 15.6 0 0.0 
Piscataquis 0 0.0 1 5.8 0 0.0 7 40.5 0 0.0 
Sagadahoc 1 2.8 2 5.7 0 0.0 5 14.2 1 2.8 
Somerset 0 0.0 6 11.6 0 0.0 32 61.6 0 0.0 
Waldo 2 5.2 1 2.6 0 0.0 3 7.7 0 0.0 
Washington 0 0.0 2 6.2 0 0.0 4 12.3 0 0.0 
York 2 1.0 2 1.0 2 1.0 33 16.6 3 1.5 
Maine Total 37 2.8 102 7.7 17 1.3 258 19.4 10 0.8 
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Reportable HIV/STDs, Number of Cases and Rate per 100,000 Persons by County, Maine, 2012 
 Chlamydia Gonorrhea Syphilis, Primary and 
Secondary* 
HIV 
County No. Rate No. Rate No. Rate No. Rate 
Androscoggin 457 424.7 193 179.4 0 0.0 6 5.6 
Aroostook 103 145.3 7 9.9 0 0.0 0 0.0 
Cumberland 746 262.7 117 41.2 10 3.5 20 7.0 
Franklin 75 244.9 1 3.3 0 0.0 0 0.0 
Hancock 108 198.0 9 16.5 2 3.7 3 5.5 
Kennebec 367 301.2 31 25.4 5 4.1 8 6.6 
Knox 76 191.6 6 15.1 0 0.0 1 2.5 
Lincoln 62 181.4 3 8.8 0 0.0 0 0.0 
Oxford 114 198.3 1 1.7 0 0.0 0 0.0 
Penobscot 432 281.0 22 14.3 0 0.0 2 1.3 
Piscataquis 37 214.0 0 0.0 0 0.0 0 0.0 
Sagadahoc 85 241.5 10 28.4 0 0.0 0 0.0 
Somerset 92 177.2 12 23.1 1 1.9 0 0.0 
Waldo 55 141.7 3 7.7 0 0.0 0 0.0 
Washington 83 255.7 6 18.5 0 0.0 2 6.2 
York 521 261.8 35 17.6 1 0.5 6 3.0 
Maine Total 3413 256.8 456 34.3 19 1.4 48 3.6 
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Reportable Conditions, Number of Confirmed and Probable Cases and Rate per 100,000 Persons by District*, Maine, 2012 
Condition Aroostook Central Cumberland Downeast Mid Coast 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Anaplasmosis 0 0.0 3 1.7 10 3.5 3 3.4 18 12.2 
Babesiosis 0 0.0 1 0.6 3 1.1 0 0.0 2 1.4 
Campylobacteriosis 7 9.9 27 15.5 43 15.1 10 11.5 18 12.2 
Chlamydia 103 145.3 459 264.2 746 262.7 191 219.5 278 188.0 
Cryptosporidiosis 5 7.1 17 9.8 8 2.8 2 2.3 6 4.1 
Ehrlichia chaffeensis 0 0.0 0 0.0 0 0.0 0 0.0 2 1.4 
Giardiasis 6 8.5 30 17.3 50 17.6 10 11.5 18 12.2 
Gonorrhea 7 9.9 43 24.7 117 41.2 15 17.2 22 14.9 
Haemophilus influenzae, invasive 1 1.4 2 1.2 6 2.1 2 2.3 3 2.0 
Hemolytic uremic syndrome 0 0.0 0 0.0 2 0.7 0 0.0 0 0.0 
HIV 0 0.0 8 4.6 20 7.0 5 5.7 1 0.7 
Hepatitis A 0 0.0 1 0.6 5 1.8 0 0.0 0 0.0 
Hepatitis B, acute 1 1.4 0 0.0 3 1.1 1 1.1 1 0.7 
Hepatitis B, chronic 2 2.8 7 4.0 54 19.0 6 6.9 4 2.7 
Legionellosis 1 1.4 4 2.3 2 0.7 3 3.4 2 1.4 
Listeriosis 1 1.4 1 0.6 0 0.0 0 0.0 0 0.0 
 
  
*See map in Appendix J for location of districts 
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Reportable Conditions, Number of Confirmed and Probable Cases and Rate per 100,000 Persons by District*, Maine, 2012 
Condition Penquis Western York State 
No. Rate No. Rate No. Rate No. Rate 
Anaplasmosis 1 0.6 1 0.5 16 8.0 52 3.9 
Babesiosis 1 0.6 0 0.0 3 1.5 10 0.8 
Campylobacteriosis 31 18.1 26 13.3 27 13.6 189 14.2 
Chlamydia 469 274.2 646 330.1 521 261.8 3413 256.8 
Cryptosporidosis 15 8.8 2 1.0 3 1.5 58 4.4 
Ehrlichia chaffeensis 0 0.0 0 0.0 1 0.5 3 0.2 
Giardiasis 14 8.2 27 13.8 14 7.0 169 12.7 
Gonorrhea 22 12.9 195 99.6 35 17.6 456 34.3 
Haemophilus influenzae, invasvie 1 0.6 5 2.6 3 1.5 23 1.7 
Hemolytic uremic syndrome 0 0.0 0 0.0 0 0.0 2 0.2 
HIV 2 1.2 6 3.1 6 3.0 48 3.6 
Hepatitis A 0 0.0 2 1.0 1 0.5 9 0.7 
Hepatitis B, acute 2 1.2 0 0.0 1 0.5 9 0.7 
Hepatitis B, chronic 7 4.1 14 7.2 11 5.5 105 7.9 
Legionellosis 2 1.2 4 2.0 0 0.0 18 1.4 
Listeriosis 0 0.0 1 0.5 2 1.0 5 0.4 
*See map in Appendix J for location of districts 
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Reportable Conditions, Number of Confirmed and Probable Cases and Rate per 100,000 Persons by District*, Maine, 2012 
Condition Aroostook Central Cumberland Downeast Mid Coast 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Lyme Disease 1 1.4 139 80.0 266 93.7 66 75.8 288 194.8 
Meningococcal invasive disease 0 0.0 0 0.0 1 0.4 0 0.0 0 0.0 
MRSA, invasive 18 25.4 19 10.9 31 10.9 4 4.6 11 7.4 
Mumps 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Pertussis 5 7.1 166 95.5 225 79.2 46 52.9 37 25.0 
Rabies, animal 0  15  10  0  26  
Salmonellosis 4 5.6 32 18.4 34 12.0 14 16.1 9 6.1 
Shiga toxin producing E. coli 0 0.0 4 2.3 7 2.5 2 2.3 0 0.0 
Shigellosis 0 0.0 0 0.0 4 1.4 0 0.0 0 0.0 
Streptococcus, invasive Group A 2 2.8 9 5.2 6 2.1 0 0.0 5 3.4 
Streptococcus pneumoniae, 
invasive  9 12.7 22 12.7 17 6.0 5 5.7 9 6.1 
Syphilis 0 0.0 6 3.5 10 3.5 2 2.3 0 0.0 
Tuberculosis 1 1.4 0 0.0 10 3.5 1 1.1 0 0.0 
Varicella (chickenpox) 10 14.1 58 33.4 66 23.2 15 17.2 24 16.2 
Vibriosis 0 0.0 0 0.0 6 2.1 0 0.0 1 0.7 
*See map in Appendix J for location of districts 
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Reportable Conditions, Number of Confirmed and Probable Cases and Rate per 100,000 Persons by District*, Maine, 2012 
Condition Penquis Western York State 
No. Rate No. Rate No. Rate No. Rate 
Lyme Disease 23 13.4 111 56.7 217 109.0 1111 83.6 
Meningococcal invasive disease 0 0.0 1 0.5 1 0.5 3 0.2 
MRSA, invasive 14 8.2 11 5.6 8 4.0 116 8.7 
Mumps 0 0.0 0 0.0 0 0.0 0 0.0 
Pertussis 91 53.2 97 49.6 70 35.2 737 55.5 
Rabies, animal 15  14  11  91  
Salmonellosis 12 7.0 22 11.2 34 17.1 161 12.1 
Shiga toxin producing E. coli 2 1.2 0 0.0 5 2.5 20 1.5 
Shigellosis 0 0.0 1 0.5 2 1.0 7 0.5 
Streptococcus, invasive Group A 7 4.1 6 3.1 2 1.0 37 2.8 
Streptococcus pneumoniae, 
invasive  21 12.3 17 8.7 2 1.0 102 7.7 
Syphilis  0 0.0 0 0.0 1 0.5 19 1.4 
Tuberculosis 0 0.0 3 1.5 2 1.0 17 1.3 
Varicella 31 18.1 21 10.7 33 16.6 258 19.4 
Vibriosis 0 0.0 0 0.0 3 1.5 10 0.8 
*See map in Appendix J for location of districts 
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Anaplasmosis 
2012 Case Total 52 
Maine Rate 3.9 per 100,000 
U.S. rate (2011) 0.8 per 100,000 
Anaplasmosis Incidence, Maine and US, 
2008-2012
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Anaplasmosis is a disease caused by the 
bacterium Anaplasma phagocytophili-
um.   Anaplasmosis was previously 
known as human granulocytic ehrlichio-
sis (HGE) or human granulocytic ana-
plasmosis (HGA).   
 
Signs and symptoms of anaplasmosis 
include:  fever, headache, malaise, and 
body aches.  Anaplasmosis is transmit-
ted to a person by the bite of an infected 
deer tick (Ixodes scapularis), one of the 
most common ticks in Maine. 
 
 52 cases represent an  increase from 
26 cases in 2011 
 The 2007-2011 median number of 
cases per year was 17 
 Median age was 59 years 
 Age range was 19 to 86 years 
 Cases were 15% female and 85% 
male 
 Greatest number of cases occurred 
during the spring and summer months 
 
The best way to prevent infection is to 
take measures to protect against tick 
bites.  Checking for ticks after visiting a 
tick infested area is an important way to 
reduce the risk of contracting            
anaplasmosis. Using EPA approved  
repellents such as DEET on skin or    
permethrin on clothing is a good way to 
protect against tick bites. Always follow 
the instructions on the label when     
applying repellent products. If an      
engorged tick is found, it should be 
safely removed and saved for           
identification. Monitor for signs and 
symptoms for 30 days after the tick bite. 
 
For more information about submitting 
a t ick for identi f icat ion only              
(not testing) visit www.mmcri.org/lyme.    *onset date missing for two cases 
21
Babesiosis 
2012 Case Total 10 
Maine Rate 0.8 per 100,000 
U.S. rate (2011) 0.4 per 100,000 
Babesiosis Incidence, Maine, 2008-2012
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Babesiosis is caused by a parasite that 
may be carried by ticks.  Many individ-
uals that get the disease do not have 
symptoms.  Serious symptoms can oc-
cur, especially in persons who are im-
munosuppressed, those without a 
spleen, or people who are co-infected 
with Lyme disease.  Babesiosis may 
also occur after a blood transfusion 
from an infected donor. 
 
Common symptoms include: extreme 
fatigue, aches, fever, chills, sweating, 
dark urine, and possibly anemia.   
 
 10 cases represent an increase from  9 
cases in 2011 
 The 2007-2011 median number of 
cases was 9 
 Median age was 54 years 
 Age range was 41 to 73 years 
 Cases were 20% female and 80% 
male 
 Greatest number of cases occurred 
during the summer months 
 
The best way to prevent infection is to 
take measures to protect against tick 
bites.  Checking for ticks after visiting a 
tick infested area is an important way to 
reduce the risk of contracting babesio-
sis.  Using EPA approved repellents 
such as DEET on skin or permethrin on 
clothing is a good way to protect against 
tick bites. Always follow the instruc-
tions on the label when applying repel-
lent products. If an engorged tick is 
found, it should be safely removed and 
saved for identification. Monitor for 
signs and symptoms for 30 days after 
the tick bite. 
 
For more information about submitting 
a tick for identification only (not test-
ing) visit www.mmcri.org/lyme.    
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Campylobacteriosis 
2012 Case Total 189 
Maine Rate 14.2 per 100,000 
U.S. rate (2011) Not reportable 
Campylobacteriosis Incidence, Maine, 
2008-2012
0
2
4
6
8
10
12
14
16
2008 2009 2010 2011 2012
Year
C
as
es
 p
er
 1
00
,0
00
Campylobacteriosis by Age and Gender, Maine, 
2012
0
5
10
15
20
25
30
0-4 5-14 15-24 25-34 35-44 45-54 55-64 65+
Age group
C
as
es
Male Female
Campylobacteriosis by Month of Report, Maine, 
2012
0
5
10
15
20
25
30
35
Ja
n
Fe
b
Ma
r
Ap
r
Ma
y
Ju
n Ju
l
Au
g
Se
p
Oc
t
No
v
De
c
Month
C
as
es
Campylobacteriosis is one of the most 
common infectious diseases causing 
diarrhea in the United States.  Symp-
toms include: diarrhea, cramping, ab-
dominal pain and fever. Most people 
recover within 5 to 10 days.  
 
Campylobacteriosis is associated with 
handling raw poultry or eating under-
cooked poultry meat, consuming unpas-
teurized milk and other dairy products 
and from exposure to contaminated 
foods. Raw foods, such as vegetables or 
salad, can be contaminated if the same 
cutting board or utensils are used for 
both raw foods and raw poultry items 
and not cleaned between preparations.  
 
 189 cases represent a decrease from 
195 cases in 2011 
 The 2007-2011 median number of 
cases was 151   
 Median age was 50 years 
 Age range was 7 months to 90 years 
 Cases were 52% female and 48% 
male 
 Highest rates in Cumberland, Pe-
nobscot, York, and Kennebec coun-
ties 
 Greatest number of cases occurred 
during the summer months  
 
To prevent illness, individuals should 
cook poultry and other meats properly, 
avoid consuming untreated water, raw 
milk and milk products, and unpasteur-
ized juice. 
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Chlamydia 
2012 Case Total 3,413 
Maine Rate 256.8 per 100,000 
U.S. rate (2011) 457.6 per 100,000 
Chlamydia Incidence, Maine and US, 2008-2012
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Chlamydia is a sexually transmitted dis-
ease (STD) caused by the bacterium 
Chlamydia trachomatis.  Chlamydia is 
known as a “silent” disease, as three 
quarters (75%) of women and half 
(50%) of men infected with chlamydia 
will have no symptoms.  Common 
symptoms for women include vaginal 
discharge or a burning sensation with 
urination and for men include penile 
discharge and burning on urination.  
 
If chlamydia is not treated, the infection  
may cause serious damage to the repro-
ductive system, including infertility.  
Chlamydia can be passed to a child dur-
ing birth.  People with chlamydia can 
more easily contract HIV from someone 
else  or transmit HIV to others if they 
are infected with both.    
   
 Chlamydia is the most frequently 
reported STD in Maine 
 71% of infections were in persons 
15-24 years old 
 Cases were 71% female and 29% 
male 
 
Chlamydia can be prevented by the use 
of latex or polyurethane condoms and 
dental dams during anal, vaginal, and 
oral sex. Efforts to prevent the spread of 
chlamydia include prioritized follow up 
activities for new diagnoses  and the 
Infertility Prevention Project, a federal 
CDC sponsored initiative, that targets 
testing and treatment for females 15-24 
years old and their partners.  Currently 
free testing for females 15-24 is availa-
ble at Family Planning and Planned 
Parenthood sites, and at the three STD 
clinics (Bangor, Portland and Lewis-
ton).  
 
 
 
*unknown age for 13 cases. 
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Cryptosporidiosis 
2012 Case Total 58 
Maine Rate 4.4 per 100,000 
U.S. rate (2011) 3.0 per 100,000 
Cryptosporidiosis Incidence, Maine and US, 2008-
2012
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Cryptosporidiosis is an infection most 
frequently associated with contaminated 
water or contact with infected animals. 
The disease is caused by a parasite that 
lives in the intestines of animals and 
infected humans.  Feces containing the 
parasite may contaminate the ground or 
water sources.  The parasite may live 
for long periods of time in the environ-
ment due to a protective outer covering. 
It is resistant to many chlorine-based 
disinfectants, increasing the risk of 
transmission in swimming pools and 
waterparks. 
 
Symptoms include: diarrhea, abdominal 
cramping, malaise and vomiting. 
 
 58 cases represent an increase from 
51 cases in 2011 
 The 2007-2011 median number of 
cases per year was 56 
 Median age was 30 years 
 Age range was 1 year to 97 years 
 Cases were 48% female and 52% 
male 
 Highest incidence was in Kennebec, 
Penobscot, Cumberland, and Somer-
set counties  
 
Preventive measures include consuming 
pasteurized milk and dairy products, 
practicing good hand hygiene around 
farm animals and discouraging  persons 
of all ages from swimming when they 
have diarrheal illness. 
*onset date missing for one case 
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Giardiasis 
2012 Case Total 169 
Maine Rate 12.7 per 100,000 
U.S. rate (2011) 5.4 per 100,000 
Giardiasis Incidence, Maine and US, 2008-2012
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Giardiasis is sometimes known as 
“beaver fever” because beavers (as well 
as dogs, cats, horses and cows) are ma-
jor reservoirs for the parasite (Giardia 
lamblia) that causes the infection. The 
parasite lives in the intestines of infect-
ed humans and animals and when ex-
pelled through the feces can contami-
nate water and  surfaces. If hikers or 
others drink water without proper treat-
ment they may become infected. Young 
children in child care or pool settings 
who are prone to sucking on toys or 
swallowing water are also at higher risk. 
 
 169 cases represent a decrease from 
171 cases in 2011 
 The 2007-2011 median number of 
cases per year was 197 
 Median age was 39 years 
 Age range was 1 year to 83 years 
 Cases were 54% female and 46% 
male 
 Highest incidence was in Cumber-
land, Kennebec, Androscoggin, and 
York counties 
 Greatest number of cases occurred 
during the late summer  and fall 
months 
 
Individuals can prevent this illness by 
not drinking from untreated water 
sources, such as streams and lakes.  In-
creased attention to proper sanitation 
and hygiene in public water recreational 
facilities can help to reduce the trans-
mission of Giardia. 
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Gonorrhea 
2012 Case Total 456 
Maine Rate 34.3 per 100,000 
U.S. rate (2011) 104.2 per 100,000 
Gonorrhea Incidence, Maine and US, 2008-2012
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Gonorrhea is a sexually transmitted dis-
ease (STD) caused by the bacterium 
Neisseria gonorrhoeae that grows and 
multiplies in warm, moist areas 
(mucous membranes).  Gonorrhea can 
be spread through contact with the vagi-
na, penis, mouth or anus.  Gonorrhea 
can also spread from a mother to her 
baby during childbirth.  Gonorrhea does 
not always cause symptoms.  Men may 
feel a burning sensation while urinating, 
or have  discharge from their penis.  
Women might feel pain with urination, 
or notice discharge from their vagina.   
 
Gonorrhea is dangerous if untreated.  In 
women, gonorrhea is a common cause 
of pelvic inflammatory disease, which 
can lead to chronic pain and infertility.  
In men, gonorrhea can cause epididy-
mitis, causing painful testicles and  in-
fertility.  People infected with HIV are 
more likely to contract gonorrhea and to 
transmit HIV if they are also infected 
with gonorrhea.     
 
 Case total of 456 represents a 68% 
increase from 272 cases in 2012 
 Highest incidence was among per-
sons 25-39 years, with a total of 43% 
of cases, followed closely by persons 
15-24 years with 41% of cases  
 Cases were fairly evenly distributed 
with 53% female and 47% male 
 
Gonorrhea can be prevented by using 
latex or polyurethane condoms and den-
tal dams during anal, vaginal, and oral 
sex. Prevention efforts include treatment 
verification and case investigation activ-
ities, such as partner follow-up for all 
new  infections. State sponsored testing 
through the Infertility Prevention Pro-
ject uses a combination gonorrhea and 
chlamydia test targeting females 15-24 
years old. 
Gonorrhea by Month, Maine, 2012
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Group A Streptococcal 
Disease 
2012 Case Total 37 
Maine Rate 2.8 per 100,000 
U.S. rate (2011) Not reportable 
Invasive GAS Incidence, Maine, 2008-2012
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Group A Streptococcus (GAS) is a bac-
terium often found in the throat and on 
the skin that can cause either no symp-
toms (colonization) or mild symptoms 
such as pharyngitis (strep throat), cellu-
litis (soft tissue infection) or impetigo 
(skin dermatitis).  When the bacteria 
enters deeper tissues and the blood 
stream, GAS can cause severe or life-
threatening conditions. 
 
GAS may lead to Streptococcal Toxic 
Shock Syndrome (STSS), a rapid drop 
in blood pressure that causes organ fail-
ure. 
Necrotizing fasciitis, a condition that 
progressively destroys skin, fat and 
muscles, can be caused by GAS.   
 
 37 cases represent a decrease from 43 
cases in 2011 
 The 2007-2011 median number of 
cases per year was 28 
 Median age was 47 years 
 Age range was 3 months to 104 years 
 Cases were 46% female and 54% 
male 
 5 GAS cases died 
 10 (27%) cases were also diagnosed 
with STSS; 4 of these cases died 
 
Control and prevention strategies may 
include targeted chemoprophylaxis for 
high risk household contacts of con-
firmed cases, such as those who are 65 
and older or those who have other speci-
fied risk factors (HIV infection, diabe-
tes, malignancy, injecting drug use, or 
cardiac diseases). 
*age missing for one case 
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Haemophilus influenzae 
2012 Case Total 23 
Maine Rate 1.7 per 100,000 
U.S. rate (2011) 1.1 per 100,000 
Haemophilus influenzae Incidence, Maine and 
US, 2008-2012
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Haemophilus influenzae disease is 
caused by the Haemophilus influenzae 
bacterium.  A specific type called H. 
influenzae serotype B (Hib) was once 
the most common cause of bacterial 
meningitis in children.  Due to wide-
spread use of Hib vaccine, few or no 
cases are reported in children less than 5 
years old each year.   
 
The bacteria are spread from person to 
person, through airborne droplets when 
an infected person coughs or sneezes.  
H. influenzae can cause severe illnesses 
such as meningitis, bacteremia, pneu-
monia and septic arthritis. 
 
 23 cases represent a decrease from 26 
cases in 2011 
 The 2007-2011 median number of 
cases per year was 21 
 Median age was 66 years 
 Age range was 6 days to 93 years 
 Cases were 61% female and 39% 
male 
 No cases of Hib (type b) in children 
aged < 5 years were reported 
 
Haemophilus influenzae serotype b 
(Hib) may be prevented in children 
through vaccination.  Vaccination is 
recommended for all children at ages 2, 
4 and 6 months or at 2 and 4 months 
depending on the type of vaccine availa-
ble.  An additional booster dose is given 
at 12-15 months of age with either type 
of vaccine. 
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Hepatitis A 
2012 Case Total 9 
Maine Rate 0.7 per 100,000 
U.S. rate (2011) 0.5 per 100,000 
Hepatitis A Incidence, Maine and US, 2008-2012
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Hepatitis A is a liver disease caused by 
the hepatitis A virus. The virus is spread 
from person to person by fecal-oral 
transmission that involves putting some-
thing in the mouth (such as food, hands 
or water) that has been contaminated by 
a person infected with hepatitis A.  Poor 
handwashing by persons with  hepatitis 
A increases the risk of transmission. 
The virus spreads more easily in areas 
where sanitary conditions and personal 
hygiene practices are poor.  Most infec-
tions result from exposure during inter-
national travel, or contact with a house-
hold member or a sexual partner who 
has hepatitis A. 
 
Onset of symptoms is usually abrupt 
with fever, malaise, anorexia, nausea 
and abdominal discomfort followed by 
jaundice a few days later. Children are 
often asymptomatic. Upon recovery, a 
person is immune to hepatitis A for life.  
 
 9 cases represent an increase from 6 
cases in 2011 
 The 2007-2011 median number of 
cases per year was 6 
 Median age was 41 years 
 Age range was 1 year to 87 years 
 Cases were 22% female and 78% 
male 
 
Washing hands after using the bath-
room, changing a diaper, or before pre-
paring or eating food can help prevent 
infection. Hepatitis A can also be pre-
vented through vaccination. The two 
dose vaccine series is recommended for 
all children at 12 months of age and for 
persons who are more likely to be ex-
posed to hepatitis A or become serious-
ly ill if they get hepatitis A.  The vac-
cine is also recommended for some 
travelers and for close contacts of newly 
arriving international adoptees. 
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Hepatitis B, acute 
2012 Case Total 9 
Maine Rate 0.7 per 100,000 
U.S. rate (2011) 0.9 per 100,000 
Acute Hepatitis B Incidence, Maine and US, 
2008-2012
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Hepatitis B is a liver disease caused by 
the hepatitis B virus. Acute hepatitis B 
infection occurs within the first six 
months after someone is exposed to the 
virus. In some cases, acute infection can 
lead to chronic infection. The younger 
the age at time of infection, the greater 
the likelihood of progressing to chronic 
hepatitis B infection. 
 
Hepatitis B virus can be transmitted 
through exposure to blood or body flu-
ids from an infected person (needle 
sticks and other sharps exposures, shar-
ing hypodermic syringes for drug injec-
tion), through sexual contact with an 
infected person, or from an infected 
mother to her child during childbirth.  
Sexual transmission is common among 
men who have sex with men.  
 
Symptoms include anorexia, abdominal 
discomfort, nausea and vomiting fol-
lowed by jaundice. Many young chil-
dren and immunosuppressed adults do 
not develop symptoms. 
 
 9 cases represent an increase from 8 
cases in 2011  
 The 2007-2011 median number of 
cases per year was 15 
 Median age was 44 years 
 Age range was 19 to 64 years 
 Cases were 44% female and 56% 
male 
 
Hepatitis B can be prevented by vac-
cination as well as by not sharing nee-
dles and other drug injecting equipment, 
using sterile needles and syringes, and 
using condoms. Hepatitis B can also be 
prevented by not sharing equipment for 
blood glucose monitoring and insulin 
administration. 
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Hepatitis B, chronic 
2012 Case Total 105 
Maine Rate 7.9 per 100,000 
U.S. rate (2011) Not available 
Newly Reported Cases of Chronic 
Hepatitis B, Maine, 2008-2012
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Hepatitis B is a liver disease caused by 
the hepatitis B virus. Chronic hepatitis 
B virus infection occurs when a person 
infected with acute hepatitis B does not 
clear the virus within the first 6 months 
of infection. 
 
Chronic hepatitis B is a serious disease 
that can result in long-term health prob-
lems, such as cirrhosis (scarring) of the 
liver, liver cancer, liver failure, and 
even death. Many people do not have 
symptoms and may not know they are 
infected, but they can still spread the 
disease to others. 
 
Hepatitis B virus can be transmitted 
through exposure to blood and or body 
fluids from an infected person (needle 
sticks and other sharps exposures, shar-
ing hypodermic syringes for drug injec-
tion), through sexual contact with an 
infected person, or from an infected 
mother to her child during childbirth.  
Sexual transmission also occurs among 
men who have sex with men.  
 
 105 cases represent no change from 
2011 
 Median age was 39 years 
 Age range was 3 to 75 years 
 Cases were 39% female and 61% 
male 
 
Hepatitis B can be prevented through 
testing and vaccination of susceptible 
household and sexual contacts of identi-
fied cases. Transmission can be prevent-
ed by not sharing needles or other drug 
injecting equipment, using sterile nee-
dles and syringes, and using condoms. 
Hepatitis B can also be prevented by not 
sharing equipment for blood glucose 
monitoring and insulin administration. 
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Hepatitis C, acute 
2012 Case Total 8 
Maine Rate 0.6 per 100,000 
U.S. rate (2011) 0.4 per 100,000 
Acute Hepatitis C Incidence, Maine and US, 
2008-2012
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Hepatitis C is a liver disease caused by 
the hepatitis C virus. Acute hepatitis C 
is a short term illness that occurs within 
the first 6 months after someone is ex-
posed. Hepatitis C is spread when blood 
from a person infected with hepatitis C 
enters the body of someone who is not 
infected. Many people become infected 
by sharing needles or other injection 
drug equipment. 
 
Persons with acute or newly acquired 
hepatitis C infection are usually asymp-
tomatic or have mild symptoms. Ap-
proximately 20–30% of persons with 
acute infection experience fatigue, ab-
dominal pain, poor appetite, and/or 
jaundice.  The average time period from 
exposure to symptom onset is 4–12 
weeks (range: 2–24 weeks). Other 
symptoms of acute infection include: 
fever, dark urine, clay-colored stool,  
nausea, vomiting, and joint pain. 
 8 cases represent a decrease from 12 
cases in 2011 
 The 2007-2011 median number of 
cases per year was 2 
 Median age was 44 years 
 Age range was 27 to 53 years 
 Cases were 62% female and 38% 
male. 
 
To prevent acute hepatitis C, do not 
share needles or equipment used to in-
ject drugs. Do not share personal hy-
giene items.  Use licensed tattooists and 
body piercers. Use condoms to  reduce 
the already low risk of sexual transmis-
sion.  
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Hepatitis C, past or pre-
sent infection 
2012 Case Total 1,216 
Maine Rate 91.5 per 100,000 
U.S. rate (2011) N/A 
Newly Reported Cases of Past or Present Hepatitis 
C Infection, Maine, 2008-2012
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Hepatitis C is a liver disease caused by 
the hepatitis C virus. Past or present 
hepatitis C infection is a long-term ill-
ness that occurs when hepatitis C virus 
remains in a person’s body. Over time it 
can lead to serious liver disease. Hepati-
tis C is spread when blood from a per-
son infected with hepatitis C enters the 
body of someone who is not infected. 
Many people become infected by shar-
ing needles or other injection drug 
equipment. 
 
Most people with hepatitis C infection 
do not have any symptoms. In many 
cases, symptoms only appear when liver 
problems develop. Hepatitis C is often 
detected during routine blood tests to 
measure liver function and liver enzyme 
levels. As of January 1, 2012 Hepatitis 
C, past or present infection, is reported 
to U.S. CDC using their case definition.  
 
 1,216 cases represent an  
    increase from 1184 cases in 2011 
Median age was 38 years 
 Age range was 4 months to 89 years 
 Cases were 42% female and 58% 
male 
 
People with past or present hepatitis C 
infection should be monitored regularly 
by an experienced  healthcare provider. 
They should avoid alcohol and  check 
with a health professional before taking 
any prescription pills, supplements, or 
over-the-counter medications, as these 
can potentially damage the liver. Vac-
cination against hepatitis A and hepatitis 
B is also recommended. 
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Hepatitis C Infection by Month of Report, Maine, 
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*Age missing for one case and gender missing for one case. 
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HIV* 
2012 Case Total 48 
Maine Rate 3.6 per 100,000 
U.S. rate (2011) 19.1 per 100,000 
Newly Identified HIV Diagnoses, Maine and US, 
2008-2012
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Human immunodeficiency virus (HIV) 
is a virus that is responsible for HIV 
disease and acquired immuno-
deficiency syndrome (AIDS). AIDS 
typically presents as the late clinical 
stage of HIV infection. HIV is transmit-
ted  from person to person through un-
protected penile-vaginal or penile–anal 
intercourse with an infected person; the 
use of HIV contaminated needles and 
syringes; from infected mother to infant 
during pregnancy, delivery, or breast-
feeding; and transfusion of infected 
blood or its components. In Maine, the 
most common mode of HIV transmis-
sion is through unprotected penile-anal 
intercourse among men.  
 
 Case total of 48 represents a decrease 
from 54 cases in 2011  
 The 2007-2011 median number of 
cases per year was 52 
 Age range was 3 years to 75 years  
 Majority of cases were male (73%) 
 58% of cases reported risk factor of 
males who have sex with other males 
  
HIV transmission can be prevented by 
the use of latex or polyurethane con-
doms during anal and vaginal sex.  It is 
equally important to always use clean 
needles and injection equipment when 
injecting any substance.  HIV testing, 
counseling, and referral services are 
offered by various agencies and pro-
grams dedicated to HIV prevention and 
treatment in Maine.   
*Includes all newly identified HIV infections, including those simultaneously diagnosed as new AIDS cases.  
Mode of Transmission New  
Diagnoses 
Men who have sex with men (MSM) 28 
Injection drug users (IDU) 0 
MSM and IDU 0 
Heterosexual contact with at-risk partners 5 
Heterosexual, no at-risk partners disclosed 14 
Undetermined 0 
Received contaminated  blood products 0 
Child born to mother with HIV 1 
% of  
Cases 
58% 
0% 
0% 
11% 
29% 
0% 
0% 
2% 
Reported Transmission Risk Factors Among Persons  
Diagnosed with HIV, 2012 
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Legionellosis 
2012 Case Total 18 
Maine Rate 1.4 per 100,000 
U.S. rate (2011) 1.4 per 100,000 
Legionellosis Incidence, Maine and US, 
2008-2012
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Legionellosis (or Legionnaire’s disease) 
is a serious and sometimes fatal form of 
pneumonia. Legionella bacteria are 
widespread in natural, industrial and 
recreational water sources.  The bacteria 
grow best in warm, stagnant water.  
They can be found in creeks and ponds, 
hot and cold water taps, hot water tanks, 
water cooling towers, and condensers of 
large air-conditioning systems.  People 
get legionellosis when they breathe in a 
mist or vapor that is contaminated with 
the bacteria.  Persons at high risk of get-
ting legionellosis include those who are 
middle aged or older, smoke, have 
chronic lung disease, or weakened im-
mune systems due to cancer, kidney 
failure, diabetes, or HIV infection. 
 
Symptoms include: high fever, chills, 
muscle aches, headaches, cough, and 
pneumonia.  Legionellosis is treatable 
with antibiotics.  
 
 18 cases represent no change from 
2011 
 The 2007-2011 median number of 
cases per year was 11 
 Median age was 59 years 
 Age range was 34 to 85 years 
 Cases were 17% female and 83% 
male 
 
Prevention depends on good mainte-
nance of possible water sources of in-
fection (water tanks, water systems, 
fountains, etc.). This includes regular 
cleaning, disinfecting, and applying  
other physical (temperature) or chemi-
cal measures to minimize growth.  Ap-
plying such controls at hospitals, indus-
trial sites, hotels, and recreation centers 
will reduce the risk of water contamina-
tion. *Onset date missing for one case 
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Listeriosis 
2012 Case Total 5 
Maine Rate 0.4 per 100,000 
U.S. rate (2011) 0.3 per 100,000 
Listeriosis Incidence, Maine and US, 2008-2012
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Listeriosis is a bacterial illness, caused 
by Listeria monocytogenes. Infection 
may cause sepsis and meningitis.  Lis-
teriosis is frequently linked to ready-to-
eat meats (such as paté and refrigerated 
smoked seafood), deli meats, soft chees-
es and raw milk. Pregnant women are at 
highest risk for severe outcomes as an 
infection  acquired during pregnancy 
can be transmitted to the fetus.  Also at 
risk are the elderly and individuals with 
significant health conditions like cancer, 
diabetes, liver disease, immune system 
problems, or multiple medical condi-
tions.  
 
Symptoms include: fever, headache, 
nausea, fatigue and disorientation.  Lis-
teriosis may cause spontaneous abor-
tion.  
 
 5 cases represent an increase from 4 
cases in 2011 
 The 2007-2011 median number of 
cases per year was 4  
 Median age was 81 years 
 Age range was 70 to 83 years 
 All 5 cases were hospitalized 
 
Listeria bacteria are able to multiply in 
contaminated foods even during refrig-
eration.  Poultry or meat (including hot 
dogs) should not be consumed without 
following proper cooking instructions. 
Raw milk or foods made from raw milk 
should be avoided.  Pregnant women 
and people with weakened immune sys-
tems should avoid eating such foods as 
ready-to-eat meats, hot dogs, soft chees-
es, and refrigerated smoked seafood. 
*Onset date missing for one case 
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Lyme Disease 
2012 Case Total 1,111 
Maine Rate 83.6 per 100,000 
U.S. Rate (2011) 10.6 per 100,000 
Lyme Disease Incidence, Maine and US, 
2008-2012
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Lyme disease, Maine’s most common 
vectorborne disease in humans, is 
caused by the bacterium Borrelia 
burgdorferi. The disease is transmitted 
via the bite of an infected deer tick 
(Ixodes scapularis) and symptoms are 
generally visible between 3 and 30 days 
after the initial bite. Early symptoms 
include: a characteristic “bulls eye” 
rash, fever, headache, joint and muscle 
pain, fatigue. Later symptoms include: 
arthritis, Bell’s palsy and other cranial 
nerve palsies, meningitis, and carditis.  
 
 1,111 cases represent an increase 
from 1,012 cases in 2011 
 The 2007-2011 median number of 
cases per year was 908 
 Median age was 48 years 
 Age range was 5 months to 92 years 
 Cases were 44% female and 56% 
male 
 Cases were greatest in York (20%) 
and Cumberland (24%) counties 
 
Although there is no vaccine for Lyme 
disease, risk can be greatly reduced by 
avoiding tick habitats, using EPA ap-
proved repellents (such as DEET), 
wearing long sleeves and pants, and 
checking for ticks after spending time in 
tick habitat. Landscape management 
and control of deer herds can also allow 
communities to better protect residents 
from Lyme disease. 
 
For more information about submitting 
a tick for identification (not testing for 
Lyme disease) visit www.mmcri.org/
lyme.    
Lyme Disease by Month of Report, Maine, 2012
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Meningococcal Disease 
2012 Case Total 3 
Maine Rate 0.2 per 100,000 
U.S. rate (2011) 0.2 per 100,000 
Meningococcal Disease Incidence, Maine and 
US, 2008-2012
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Meningococcal disease is an infection 
caused by Neisseria meningitidis, a 
gram-negative diplococcus bacterium. 
Meningococcal disease presents most 
commonly as meningitis and/or menin-
gococcemia that may progress rapidly to 
purpura fulminans, shock and death. 
Transmission of meningococcal disease 
most often occurs through direct contact 
with respiratory secretions from the 
nose or throat of a person with the in-
fection.  
 
Symptoms include fever, headache, and 
stiff neck for meningitis and rash and 
sepsis for meningococcemia.  The 
symptoms are indistinguishable from 
other pathogens causing  meningitis. 
 
 3 cases represent a decrease from 5 
cases in 2011 
 The 2007-2011 median number of 
cases per year was 5  
 Median age was 73 years 
 Age range was 6 to 82 years 
 Cases were 33% female and 67% 
male 
 Serogroups identified include: A (1), 
Y (1), and unknown (1) 
 
There are at least thirteen known Neis-
seria meningitidis serogroups, and there 
is currently a vaccine available for the 
four serogroups that cause the majority 
of infections (serogroups A, C, Y, and 
W-135). The vaccine is recommended 
for all adolescents, college students, 
military recruits, overseas travelers, and 
any other persons at increased risk of 
infection. To prevent the spread of dis-
ease, chemoprophylaxis is available for 
persons who have close and direct with 
a person with the infection. 
Meningococcal Disease by Age and Gender, 
Maine, 2012
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MRSA, invasive 
2012 Case Total 116 
Maine Rate  8.7 per 100,000 
U.S. rate (2011) Not reportable 
Invasive MRSA Incidence, Maine, 2008-2012
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Methicillin-resistant Staphylococcus 
aureus (MRSA) is caused by a strain of 
bacteria which is resistant to the antibi-
otic methicillin and many of the antibi-
otics commonly used to treat staphylo-
coccal infections. MRSA usually pre-
sents as a skin or soft tissue infection, 
considered a non-invasive infection.  
Invasive MRSA occurs when the bacte-
ria  infect internal systems and are iso-
lated from a normally sterile site (such 
as blood, CSF, pleural fluid or joint flu-
id) 
 
Persons with weakened immune sys-
tems, the elderly, and those with inva-
sive medical devices are at increased 
risk of invasive MRSA infections. 
 
 116 cases represent a decrease from 
121 cases in 2011 
 Median age was 66 years 
 Age range was 1 month to 93 years 
 Cases were 41% female and 59% 
male 
 
To reduce MRSA transmission cover 
wounds with clean dry bandages; wash 
hands frequently with soap and warm 
water; use disinfectants effective against 
S. aureus; avoid sharing personal items 
such as towels, washcloths, razors, and 
clothing; tell your healthcare provider if 
you had contact with someone with 
MRSA; and avoid contact sports and 
other skin-to-skin contact until your 
infection heals. Seek medical care im-
mediately to identify infection early and 
receive treatment for invasive MRSA 
infection. 
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Mosquito Borne Infections 
Mosquitoes are blood-feeding insects found 
around the world.  Female mosquitoes need a 
blood meal to reproduce, making them an im-
portant disease vector.  There are 45 species of 
mosquitoes in Maine; however less than half are 
capable of spreading diseases including EEE and 
WNV. 
 
Eastern Equine Encephalitis (EEE) 
EEE is a mosquito-borne viral disease that occurs 
in the eastern half of the United States where it 
can cause disease in humans, horses, and some 
birds.  Most persons infected with EEE will have 
no obvious symptoms.  In those persons who do 
develop illness, symptoms of EEE range from 
mild-flu like illness to inflammation of the brain, 
coma, and death.  EEE is one of the most serious 
mosquito-borne diseases in the United States be-
cause of its high mortality rate. 
 
In 2012, one pheasant tested positive for EEE  in 
Maine. Two songbirds tested positive for EEE by 
serology, indicating previous exposure to the vi-
rus, not necessarily active infection.  There were 
no human cases and no mosquito pools tested 
positive for EEE. 
 
West Nile Virus (WNV) 
WNV occurs throughout the United States and 
can cause disease in humans, birds, and other 
mammals.  Many persons infected with WNV 
will have no obvious symptoms.  In those per-
sons who do develop illness, symptoms of WNV 
include:  headache, high fever, altered mental 
state, tremors, convulsions, and rarely paralysis.  
WNV can also cause meningitis and/or encepha-
litis and can be fatal. 
 
Maine experienced its first human case of WNV 
in 2012.  The case was in a resident of Cumber-
land County with no travel history outside of 
Maine. The individual infected presented with 
neruoinvasive illness, and has since recovered. 
 
In 2012, 7 mosquito pools from York and Cum-
berland Counties tested positive for WNV in 
Maine. 
 
 
Malaria 
Malaria is a serious and sometime fatal disease 
caused by a parasite that commonly infects a cer-
tain type of mosquito.  Symptoms may include high 
fevers, shaking chills, flu-like illness, headache, 
muscle aches, tiredness, nausea, vomiting and diar-
rhea.  Malaria is uncommon in the United States, 
but very common in developing countries. 
 
In 2012, there were five cases of malaria reported 
in Maine individuals who had a history of travel 
outside the US (Burundi, Ethiopia, Sudan, and 
Uganda).  
 
Dengue Fever 
In 2012, there were no cases of Dengue fever re-
ported to the state. Dengue is a disease caused by a 
virus transmitted by the bite of an infected mosqui-
to.  Symptoms of dengue fever include high fever, 
severe headache, backache, joint pain, nausea and 
vomiting, eye pain and rash.  
 
Prevention  
To decrease risk of contracting a mosquito-borne 
disease, measures should be taken to prevent mos-
quito bites: 
 Use an EPA approved repellent. Products con-
taining DEET, IR3535, picaridin or oil of lem-
on eucalyptus can be applied to exposed skin, 
and permethrin containing products can be ap-
plied to clothing.  Make sure to follow the in-
structions on the product’s label when using 
repellents or other pesticides 
 Wear long sleeve shirts and long pants when 
possible or when mosquitoes are abundant 
 Protect babies with mosquito netting 
 When mosquitoes are abundant, stay indoors 
 Mosquito proof your house by fixing or in-
stalling window screens and screen doors 
 Control mosquito populations around your 
home by cleaning gutters and removing or 
emptying objects that contain still water where 
mosquitoes can lay eggs such as old tires, old 
cans,  and plastic tarps  
 Empty water from flower pots, pet dishes, bird-
baths, rain barrels, and buckets at least weekly 
 Prior to international travel, consult a travel 
clinic to determine if malaria prophylaxis is 
recommended for the country of visitation. 
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Pertussis 
2012 Case Total 737 
Maine Rate 55.5 per 100,000 
U.S. rate (2011) 6.0 per 100,000 
Pertussis Incidence, Maine and US, 2008-2012
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Pertussis (whooping cough) is a bacteri-
al infection of the respiratory tract 
caused by Bordetella pertussis.  Prior to 
vaccine licensure pertussis was a com-
mon childhood disease associated with a 
high mortality rate. High pertussis vac-
cination rates are associated with lower 
numbers of pertussis cases. 
 
Symptoms include an irritating cough 
lasting at least 2 weeks with paroxysm, 
whoop, and post-tussive vomiting. 
 
 737 cases represent an  increase from 
205 cases in 2011 
 The 2007-2011 median number of 
cases per year was 80 
 Median age was 10 years 
 Age range was 1 month to 83 years 
 Cases were 60% female and 40% 
male 
 Cumberland, Somerset and York 
counties had the highest incidence 
 
In 2012, clusters of illness occurred in 
schools, camps, sport teams and work-
places throughout the state. 
 
Vaccination is available and part of rou-
tine childhood immunizations.  There 
are two pertussis vaccines (DTaP and 
Tdap). The ACIP recommends all per-
sons 11 years and older receive Tdap in 
place of one tetanus booster. 
 
 
*Onset date missing for 1 case 
42
Rabies, Animal 
2012 Case Total 91 
Maine Rate N/A 
U.S. Count (2011) 6,037 
Animal Rabies, Maine, 2003-2012
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Rabies is a zoonotic viral disease that 
affects the central nervous system. All 
mammals are susceptible to rabies. Ra-
bies in humans is rare in the United 
States. The majority of rabies infections 
occur in wild animals, including rac-
coons, skunks, foxes, and bats. Unvac-
cinated domestic animals are also at risk 
for getting rabies. 
 
The rabies virus is found in the saliva 
and neural tissue of infected animals. 
Rabies is transmitted from the bite of a 
rabid animal. Rabies can also be spread 
if infectious material from a rabid ani-
mal gets into an open wound or mucous 
membrane (eyes, nose, or mouth) of a 
susceptible person or animal. Bat bites 
can be difficult to detect. Since bats are 
implicated in most human rabies cases, 
whether or not a bite was reported, any 
contact with a bat should be evaluated 
by a healthcare provider. 
 
Rabies infection causes acute progres-
sive encephalopathy. Early symptoms 
include fever and general discomfort. 
As the disease progresses, symptoms 
may include difficulty sleeping, anxiety, 
confusion, hallucinations, excessive 
drooling, difficulty swallowing, and 
hydrophobia. Rabies is almost always 
fatal a few days after symptom onset. 
 
 91 animal rabies cases represent an 
increase from 66 cases in 2011 
 85 were tested at HETL and six 
were tested at USDA as part of sup-
plemental surveillance in Northern 
Maine 
 The 2007-2011 median number of 
cases per year was 64 
 The last reported case of human 
rabies in Maine was in 1937 
 130 persons were recommended to 
receive PEP; 25 were exposed to a 
laboratory-confirmed rabid animal 
Rabies testing requires central nervous system or brain tis-
sue, obtained postmortem. The state public health laborato-
ry uses direct fluorescent antibody testing to determine if 
wild or domestic animals that expose people or domestic 
animals are rabid.   
 
Maine CDC works with Animal Control Officers, Game 
Wardens, veterinarians, and healthcare providers to recom-
mend control measures for people and domestic animals 
after an exposure. Persons who are exposed to a confirmed 
or suspect rabid animal should receive rabies post-exposure 
prophylaxis (PEP), which is a combination of rabies vac-
cine and immune globulin. Rabies PEP is very effective in 
preventing disease after an exposure. 
 
Increased public awareness about rabies may reduce the 
number of exposures. Prevention measures include keeping 
pets up-to-date on rabies vaccine and avoiding wildlife. 
Positive Rabies Results by Species, Maine, 2012 
Animal Number 
Positive 
Raccoon 45 
Skunk 30 
Fox 5 
Bat 5 
Cat  4 
Dog 1 
Woodchuck 1 
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Salmonellosis 
2012 Case Total 161 
Maine Rate 12.1 per 100,000 
U.S. rate (2011) 16.7 per 100,000 
Salmonellosis Incidence, Maine and US, 
2008-2012
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Salmonellosis is a gastrointestinal ill-
ness of varying severity caused by Sal-
monella bacteria.  Severity of symptoms 
depends on the age and overall health of 
the person infected, serotype of Salmo-
nella and the site of infection. Salmonel-
la is transmitted through the ingestion 
of contaminated meat, poultry, eggs, 
unpasteurized dairy, and fresh produce. 
Handling of reptiles, chicks, domestic 
birds, and pets can also lead to transmis-
sion. 
 
The symptoms can include: fever, 
cramping, diarrhea, nausea, and vomit-
ing.  
 
 161 cases represent an increase from 
134 cases in 2011 
 The 2007-2011 median number of 
cases per year was 134  
 Median age was 36 years 
 Age range was 1 month to 93 years 
 Cases were 59% female and 41% 
male 
 131 of 161 (81%) cases were labora-
tory confirmed 
 The most commonly seen types of 
Salmonella were Enteritidis,  New-
port and Typhimurium 
 
The best way to reduce the risk of sal-
monellosis is to wash produce, avoid 
consuming unpasteurized dairy prod-
ucts, and follow proper cooking instruc-
tions. Individuals having contact with 
reptiles (such as snakes, lizards, turtles, 
frogs, iguanas, etc.), birds, and farm 
animals should wash their hands imme-
diately after handling these animals. 
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Shiga toxin-producing  
E. coli (STEC) 
2012 Case Total 20 
Maine Rate 1.5 per 100,000 
U.S. rate (2011) 1.9 per 100,000 
STEC Incidence, Maine and US, 2008-2012
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Escherichia coli (E. coli) are common 
bacteria that live in the digestive tract, 
some cause serious infection and some 
do not. Transmission of shiga toxin-
producing E. coli (STEC) is through 
consumption of food or water contami-
nated with fecal matter or through con-
tact with farm animals. Commonly im-
plicated food items include under-
cooked meats, raw vegetables, and un-
pasteurized products.  
 
STEC may cause severe illness. Symp-
toms include: abdominal cramping, 
bloody diarrhea and a rare complication, 
hemolytic uremic syndrome (HUS), 
which can damage red blood cells and 
the kidneys. 
 
 20 cases represent a decrease from 28 
cases in 2011 
 The 2007-2011 median number of 
cases per year was 26 
 Median age was 35 years 
 Age range was 9 months to 78 years 
 Cases were 40% female and 60% 
male 
 19 of 20 (95%) cases were laboratory 
confirmed 
 42% of laboratory confirmed cases 
were O157:H7  
 2 cases of hemolytic uremic syn-
drome (HUS) with symptoms of diar-
rhea were reported, both cases were 
O157:H7 
 
STEC prevention measures include: 
handwashing, particularly before and 
after cooking and after contact with ani-
mals; thoroughly cooking meats; wash-
ing fresh fruits and vegetables; avoiding 
raw dairy products and unpasteurized 
juices; avoiding consumption of untreat-
ed water; and avoiding cross-
contamination of food items. 
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Shigellosis 
2012 Case Total 7 
Maine Rate 0.5 per 100,000 
U.S. rate (2011) 4.3  per 100,000 
Shigellosis Incidence, Maine and US, 2008-2012
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Shigellosis is a gastrointestinal illness 
caused by Shigella bacteria. Shigella is 
highly infectious and can easily be 
passed from one person to another 
through the fecal-oral route. Shigellosis 
can be transmitted by eating contami-
nated food, and drinking, swimming in 
or playing with contaminated water. 
Outbreaks of Shigella have also oc-
curred among men who have sex with 
men. 
 
Symptoms include: fever, stomach 
cramping and severe diarrhea which 
may be bloody. Children, especially 
toddlers aged 2 to 4 years, are most like-
ly to get shigellosis. 
 
 8 cases represent a decrease from 32 
cases in 2011 
 The 2007-2011 median number of 
cases per year was 14 
 Median age was 44 years 
 Age range was 11 to 79 years 
 Cases were 43% female and 57% 
male 
 5 of 7 (71%) cases were laboratory 
confirmed 
 Shigella flexneri and sonnei were 
identified 
 6/8 (75%) cases had travel to a for-
eign country during exposure period 
 
To prevent shigellosis, practice good 
hand hygiene, avoid consuming unpas-
teurized milk products,  use filtered, 
clean water, and store foods properly.  
Infected persons who are employed in 
childcare, healthcare, or food handling 
are restricted from work until infection 
clears and there is no evidence of Shi-
gella in stool specimens. Shigellosis is 
more common in the developing world 
and travelers should take extra precau-
tions. *Onset date missing for one case 
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Streptococcus pneumoniae,  
invasive  
2012 Case Total 102 
Maine Rate 7.7 per 100,000 
U.S. rate (2011) 5.5 per 100,000 
Invasive S. pneumoniae Incidence, Maine and 
US, 2010-2012
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Starting in 2010, all cases of invasive 
disease were investigated and reported. 
Prior to 2010 only drug resistant cases 
and illness in children under 5 years 
were reported to federal CDC. 
 
Invasive pneumococcal disease occurs 
when the Streptococcus pneumoniae 
bacterium infects the blood, lungs, or 
brain.  Disease is transmitted from per-
son to person through droplets when an 
infected person coughs or sneezes.  
Types of illness include bacteremia, 
meningitis, and pneumonia.  There are 
over 90 different serotypes of S. pneu-
moniae, but the majority of pneumococ-
cal disease is caused by a few common 
serotypes.   
 
Persons at risk of pneumococcal disease 
include young children, adults 65 years 
of age or older, persons with certain 
underlying medical conditions, persons 
with weakened immune systems, and 
those in congregate settings such as 
daycare and long-term care facilities. 
 
 102 cases represent a decrease from 
136 cases in 2011 
 Median age was 67 years 
 Age range was 6 months to 100 years 
 Cases were 53% female and 47% 
male 
 20 (10%) cases were drug resistant  
 3 cases were in children under the age 
of five (none were drug resistant) 
 
Pneumococcal disease can be prevented 
through routine vaccination of infants 
and children under five years with the 
pneumococcal conjugate vaccine 
(PCV13) and vaccination of adults and 
children over the age of two who are at 
high risk of infection with the pneumo-
coccal  polysacchar ide  vacc ine 
(PPSV23).  
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 Early Syphilis 
2012 Case Total 19 
Maine Rate 1.4 per 100,000 
U.S. rate (2011) 8.8 per 100,000 
Early Syphilis Incidence, Maine and US, 2008-
2012
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Syphilis is a sexually transmitted dis-
ease (STD) caused by the bacterium 
Treponema pallidum.  It has often been 
called “the great imitator” because so 
many of the signs and symptoms of 
syphilis are like those of other diseases.  
 
Early syphilis is defined as disease that 
occurs within the first year of infection.  
This is inclusive of the primary, second-
ary, and early latent stages of the dis-
ease.   
 
Syphilis is primarily spread through 
direct contact with a primary syphilis 
lesion.  Lesions typically occur on the 
external genitals, vagina, and around the 
anus, but are also seen on the lips and in 
the mouth.  Transmission primarily oc-
curs during vaginal, anal, or oral sex. 
Disease transmission can also occur 
during the infectious period of the sec-
ondary stage, via the condylomata lata 
(raised moist papules) on the genital 
area or mucous patches in the mouth.  
Pregnant women with syphilis can pass 
it to their baby.  Genital lesions caused 
by syphilis make it easier to transmit 
and acquire HIV infection.   
 
 19 cases represents a decrease from 
20 cases in 2011  
 The 2007-2011 median number of 
cases per year was 19 
 17 (89%) of cases were male, with 
only two female cases (11%)  report-
ed 
 
Many individuals infected with syphilis reach a latent stage 
and have no symptoms for years, but they are still at risk for 
later complications (damage to internal organs, nerve dam-
age, blindness and dementia) and death if not treated.  
 
Syphilis transmission can be prevented by the use of latex or 
polyurethane condoms and dental dams during anal, vaginal, 
and oral sex. Prevention and control efforts include targeted 
awareness messaging  (including the internet) and disease 
intervention activities for all early syphilis cases. Disease in-
tervention activities include ensuring adequate treatment and 
notifying partners of potential exposure.  
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Tuberculosis 
2012 Case Total 17 
Maine Rate 1.3 per 100,000 
U.S. rate (2011) 3.4 per 100,000 
Tuberculosis Incidence, Maine and US, 
2008-2012
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Tuberculosis (TB) is a communicable 
disease caused by the bacterium, Myco-
bacterium tuberculosis.  It is spread 
through the air by airborne particles 
called droplet nuclei that are expelled 
from the lungs when a person who has 
infectious TB coughs, sings or sneezes.  
TB occurs when the mycobacterium is 
inhaled into the lung and begins to mul-
tiply.  Not everyone infected with TB 
bacteria becomes sick. As a result, two 
TB-related conditions exist: latent TB 
infection (LTBI) and active TB disease. 
 
TB disease can cause infection in the 
lung (pulmonary), which is considered 
infectious to others. TB disease can also 
o c c u r  o u t s i d e  o f  t h e  l u n g 
(extrapulmonary), which is not infec-
tious. 
 
 17 cases represent an increase from 9 
cases in 2011  
 The 2007-2011 median number of 
cases per year was 9 
 Median age was 48 years 
 Age range was 3 to 88 years 
 Cases were 47% female and 53% 
male 
 10 (59%) were foreign born 
 In 9 contact investigations, 87% of 
identified contacts were evaluated 
 Of 398 LTBI reports, 84% were for-
eign born 
 
All active TB cases are evaluated by a 
TB consultant physician and are moni-
tored by the state TB Control Program 
and Public Health Nurses.  
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Varicella 
2012 Case Total 258 
Maine Rate 19.4 per 100,000 
U.S. rate (2011) 4.7 per 100,000 
Varicella Incidence, Maine and US, 2008-2012
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Varicella (chickenpox) is a highly con-
tagious viral disease of which humans 
are the only source of infection.   In 
most illness includes an itchy skin rash 
that looks like blisters, covering the 
body but  more evident on the face, 
scalp, and abdomen. The majority of 
infected individuals develop a fever just 
before or when the rash appears.  
 
Person-to-person transmission occurs 
primarily through direct contact with 
respiratory tract secretions of infected 
individuals.  Adolescents and adults are  
at higher risk for severe disease which 
could include pneumonia, bacterial in-
fection of the skin and swelling of the 
brain.  
 
 258 cases represent an increase from 
226 cases in 2011 
 Overall the greatest incidence was 
during the fall and spring months 
while schools are in session 
 Nationally varicella incidence is re-
ported to be an underestimate of true 
incidence 
 
Varicella vaccine is a live attenuated 
viral vaccine.  A two-dose series is esti-
mated to be more than 90% effective in 
preventing infection. Federal CDC and 
ACIP recommend that all children re-
ceive 2 doses of varicella vaccine. 
Breakthrough infection has been report-
ed in vaccinated individuals.  
 
Mandatory vaccination for varicella 
(one dose) began in 2003 and is a re-
quirement for school admission.   
Varicella by Age and Gender, Maine, 2012
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Vibriosis 
2012 Case Total 10 
Maine Rate 0.8 per 100,000 
U.S. rate (2011) 0.3 per 100,000 
Vibriosis Incidence, Maine and US, 2008-2012
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Vibriosis is an infection of variable se-
verity characterized by diarrhea and 
vomiting, primary septicemia, or wound 
infections. Vibrio parahaemolyticus, 
associated with ingestion of raw or un-
dercooked seafood, and Vibrio algino-
lyticus, associated with wounds and wa-
ter contact, are the primary causes of 
vibriosis in Maine. 
 
 10 cases represent an increase from 4 
cases in 2011  
 The 2007-2011 median number of 
cases was 4  
 Median age was 59 years 
 Age range was 8 to 75 years 
 Cases were 40% female and 60% 
male 
 Vibrio alginolyticus,   parahaemolyti-
cus,  and fluvialis were isolated. 
 
Due to the increase of cases in 2012, a 
collaborative team from Maine CDC, 
Department of Agriculture, Conserva-
tion and Forestry and the Department of 
Marine Resources inspected over 20 
establishments involved in processing, 
selling and preparing seafood.  
 
Vibrio infections caused by V. parahae-
molyticus can be prevented by thor-
oughly cooking seafood, especially oys-
ters.  Wound infections can be prevent-
ed by avoiding exposure of open 
wounds to seawater.   Maine CDC 
works closely with the Maine Depart-
ment of Marine Resources when per-
sons with vibriosis report having expo-
sures to shellfish or other marine 
sources of illness.  
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Influenza Season 2012—2013 
Influenza 
Influenza is a viral illness that typically occurs 
during the winter months. It is characterized by 
the abrupt onset of constitutional and respirato-
ry signs and symptoms such as fever, head-
ache, non-productive cough, sore throat, and 
runny nose.  Influenza is spread from person to 
person primarily through coughing and sneez-
ing of infected persons.  Influenza can be diag-
nosed through laboratory testing.  Influenza-
like illness (ILI) is defined as fever greater than 
or equal to 100°F (37.8°C) AND cough and/or 
sore throat in the absence of a known cause.  
 
The purpose of influenza surveillance is to 
inform influenza prevention and control policy.  
Maine CDC conducted influenza surveillance 
in collaboration with thirty six health care 
providers, four hospitals, three laboratories, 
Maine’s Electronic Death Registry System 
(EDRS), and twenty six hospital emergency 
departments during the reporting period from 
September 30, 2012 to May 18, 2013.  This 
report summarizes 2012-13 influenza 
surveillance by key indicators.   
 
 
Influenza Surveillance in Maine 
 
Outbreaks 
Outbreaks of influenza or influenza-like illness are 
reportable by law in Maine.  The definition used to 
recognize outbreaks of influenza-like illness varies 
by setting. For example, a single lab confirmed 
case (by any testing method) is an outbreak in long 
term care facilities. During the 2012-13 season, a 
total of 167 outbreaks of influenza were reported in 
Maine. This is an increase from the 2011 -12 sea-
son when 10 outbreaks were reported. Of the 167 
outbreaks, 124 were in long-term care facilities, 2 
in acute care facilities, 33 in K-12 schools, 1 in a 
university or residential school setting, 1 among 
health care workers, 5 in institutions, and 1 at a 
camp.  The number of outbreaks peaked in Januray 
(MMWR week 3) and outbreaks occurred in all 16 
counties. 
 
Death Certificates 
Maine’s EDRS was used to determine the number 
of death certificates in which pneumonia and/or 
influenza were mentioned as a cause of death.     
Data represents deaths statewide.   During the 2012
-13 season, a total of 8,091 death certificates were 
filed.  Of these 567 (7.0%) were attributed to pneu-
monia or influenza. 
 
Pediatric Fatalities 
Health care providers and the Office of the Medical 
Examiner report deaths in persons aged 18 years or 
younger associated with laboratory-confirmed in-
fluenza to Maine CDC.  One influenza-associated 
pediatric death was reported during the 2012-13 
influenza season.  A school aged child from central 
Maine died with confirmed influenza A/H3.  The 
child had not received the current year influenza 
vaccine.   
Appendix A 
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Influenza Season 2012-2013: Inpatient and Outpatient Surveillance 
Outpatient influenza-like illness (ILI) 
Data on outpatient visits for ILI  was 
collected through the U.S. Outpatient 
Influenza-like Illness Surveillance Net-
work (ILINet), a collaborative effort 
between federal CDC, Maine CDC, and 
local health care providers.  During the 
2012-13 season, 36 health care provid-
ers reported the total number of patients 
seen in their practices and the number of 
those patients seen for ILI by age group 
on a weekly basis.  Outpatient ILI visits 
in Maine peaked in December (MMWR 
week 52) The New England region also 
peaked in December.  
 
Hospital Inpatients 
Inpatient surveillance for respiratory 
illness admissions in Maine was con-
ducted in collaboration with four hospi-
tals.  During the 2012-13 season, four 
hospitals reported the number of pa-
tients admitted to the hospital and the 
number of those patients admitted for 
influenza  or pneumonia using admitting 
diagnoses.  Hospital admissions for in-
fluenza, pneumonia, or respiratory ill-
ness were highest in the first week of 
January (MMWR week 1). 
 
Emergency Room Visits 
Syndromic surveillance was conducted 
in the Emergency Departments of 26 
hospitals and analyzed using the Early 
Aberration Reporting System (EARS).  
These visits are grouped by chief com-
plaint.  The percentage of ED visits that 
had a chief complaint consistent with 
ILI peaked in early January (MMWR 
week 2) 
 
Hospital Admissions Due to Pneumonia or Influenza, Maine, 2011-13 
Emergency Department Visits for ILI at 26 Hospitals, Maine, 2011-13 
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Influenza Season 2012—2013: Laboratory Surveillance 
HETL 
Maine CDC’s Health and Environmen-
tal Testing Laboratory (HETL) worked 
collaboratively with hospitals and pri-
vate laboratories to collect specimens 
for respiratory virus testing and influen-
za positive isolate subtyping.  HETL 
reported the number of specimens re-
ceived for respiratory virus testing and 
the number positive for influenza A
(pH1N1), A (H3), A (unable to sub-
type), and influenza B by specimen col-
lection date.  During the 2012-13 sea-
son, 1,186 respiratory specimens were 
tested by HETL for influenza.  Of those 
498 (41.8%) were positive for influenza 
(18 for influenza A/pH1N1, 435 for in-
fluenza A/H3,  3 for influenza A unable 
to subtype, and 42 for influenza B). 
 
Reference Labs 
Two Maine reference laboratories, and 
many national reference laboratories 
submitted reports of laboratory-
confirmed influenza by culture or re-
verse-transcriptase polymerase chain 
reaction (RT-PCR).  During the 2012-
13 season,  1,346 specimens were posi-
tive for influenza (17 for influenza A/
pH1N1, 420 for influenza A/H3, 830 for 
influenza A without subtype, and 79 for 
influenza B). 
 
Rapid testing 
Many hospitals, labs, and physician of-
fices voluntarily report positive rapid 
antigen tests to the state.  During the 
2012-13 season 754 positive tests were 
reported, 691 for influenza A, 37 for 
influenza B, and 26 for influenza, un-
subtyped.   
Positive PCR Samples for Influenza, HETL—Maine, 2012-13 
Positive PCR Samples for Influenza, Maine and National Reference Labs 
Maine, 2012-13 
Rapid Positive Influenza Tests—Maine, 2012-13 
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Human Exposures to Marine Brucella Isolated from a                
Harbor Porpoise – Maine, 2012 
Brucellosis is a zoonotic infection caused by Brucella bacteria.  Brucella primarily affects cattle, swine, 
goats, and sheep, though many other species, including marine mammals, are susceptible to infection.  
Transmission of Brucella from animals to humans occurs through direct contact with infected animal 
tissue, secretions (blood, urine, vaginal discharge), and products of birth; ingestion of raw milk or other 
dairy products, or inhalation of  contaminated aerosols.  Symptoms of brucellosis can include fever, 
sweats, headache, back pain, and fatigue. Infection can lead to complications involving the brain,   
bones/joints, heart, liver, or spleen. Brucellosis cases in the U.S. were previously associated with       
occupational exposures in the laboratory, veterinary, and slaughter house settings; consumption of raw 
milk; or hunting. Globally, four human cases of brucellosis associated with marine Brucella spp. have 
been documented since 2001. Because Brucella is highly infectious when aerosolized, it is considered a 
bioterrorism agent, and all cases of brucellosis are immediately reportable. Brucella isolates in the     
laboratory must be handled with extreme caution at biosafety level 3 (BSL-3).      
 
In February 2012, Maine CDC was notified of a positive culture for Brucella spp. isolated from a harbor 
porpoise carcass found on the coast of southern Maine. The specimen was collected on January 29, 2012 
from the uterus of the porpoise during a routine necropsy. A sea mammal rescue team affiliated with a 
Maine university conducted the necropsy.  Two laboratories, including one out-of-state laboratory, pro-
cessed the specimen before the isolate was confirmed as marine Brucella at the U.S. CDC laboratory. In 
consultation with the U.S. CDC, Maine CDC initiated an investigation to determine potential exposures 
and provide recommendations for the testing, prophylaxis, and monitoring of exposed persons.  
 
A total of four persons were identified as high risk for potential exposure to aerosolized Brucella while 
performing the porpoise necropsy. Both laboratories used appropriate precautions when processing the 
specimen and were not at risk of exposure. Recommendations for the four exposed persons included 
baseline and serologic testing at 6 week intervals, a prophylactic three week course of doxycycline and 
rifampin, and fever/symptom monitoring for 24 weeks following the exposure. None of the four exposed 
persons had positive test results or developed symptoms consistent with brucellosis.   
 
Based on findings from an environmental assessment of the sea mammal facility where the necropsy 
was performed, the facility implemented the following recommendations to prevent additional           
exposures: 1) use of personal protective equipment when performing sea mammal exams and necrop-
sies, including respiratory protection when performing aerosol-generating procedures, 2) training for 
staff and volunteers regarding disease transmission and precautions, 3) updating policies and procedures 
to guide response in the event of occupational exposures, and 4) use of appropriate laboratory equipment 
and facility engineering updates to ensure proper air flow and filtration in the necropsy room.    
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Rabies in a Dog – Maine, 2012 
Rabies is fatal in mammals, including humans, and is prevalent in the wild animal population in Maine. 
Rabies is not prevalent in domestic animals but the number of identified rabid domestic animals in-
creased over the past few years. In 2012, a rabid dog was identified in Maine, the first rabid dog since 
2003.  
 
On July 30, 2012, Maine CDC was notified of a 62 year old Maine resident who was bitten by a dog 
three days prior. The dog died suddenly after exhibiting neurological symptoms that included an inabil-
ity to walk and see and difficulty swallowing. Given the symptoms and unknown vaccination status, it 
was recommended that the dog be submitted for rabies testing. The town’s Animal Control Officer 
(ACO) assisted in preparing the animal for rabies testing and transported the specimen to the state 
Health and Environmental Testing Laboratory (HETL) in Augusta.  The dog tested positive for  rabies 
virus on Aug 1, 2012, 5 days after the bite occurred. 
 
The man recalled that the dog was potentially bitten by a raccoon about 3 weeks prior to the dog biting 
the human, when a raccoon emerged from the woods to eat out of the dog’s outdoor food bowl. The dog 
wandered into the man’s yard 3 months prior to the bite incident and seemed friendly so the man decid-
ed to keep the dog.  The dog was not in contact with any other family members. 
  
Following the results of the positive rabies test, a thorough investigation of those who came into contact 
with the dog was conducted so that post exposure prophylaxis (PEP) could be recommended. PEP was 
only recommended for the man who cared for the dog since no other family members had contact with 
the dog. The family cared for many other stray animals that had no contact with the dog; however, it was 
recommended that those animals be brought to a veterinarian for rabies vaccination.  The ACO wore 
proper personal protective equipment while preparing the animal for testing and did not need PEP.  
 
Domestic dogs are tested for rabies if they exhibit neurological symptoms suggestive of rabies and expo-
sure humans or other domestic animals. Dogs exposed to rabid or suspect rabid animals are recommend-
ed to receive a booster dose of vaccine and 45 day observation period for vaccinated animals. Unvac-
cinated dogs are recommended to be euthanized or receive a booster dose of vaccine and 6 month isola-
tion. In 2012, 96 dogs were tested for rabies and 1 dog tested positive. In 2011, 64 dogs were tested for 
rabies and none were positive.  
 
Reports of rabies in domestic animals indicates a lapse in public health because there is an effective vac-
cine against rabies for domestic animals. The re-emergence of rabies in a dog is a concern because dogs 
cohabitate and are often in very close contact with humans.  
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Increase in Gonorrhea – Maine, 2012 
Gonorrhea is a sexually transmitted disease caused by the bacterium Neisseria gonorrhea and is              
reportable to Maine CDC. Reported gonorrhea cases increased 68% from 2011 to 2012 with notable ge-
ographic disparities.  In the most recent five year period, gonorrhea cases increased from 96 cases in 
2008 to 272 cases in 2011. In 2012, case reports increased substantially to 456.  In 2012, the statewide 
rate is 34.3/100,000 population. Androscoggin and Cumberland counties both exceeded this with rates 
of 179.4/100,000 and 41.2/100,000 population respectively. In 2011, the U.S. average rate was 
104.2/100,000 population.  
 
Regional patterns vary throughout the state with highest case reporting in southern and central Maine.  
Androscoggin (N=193) and Cumberland (N=117) counties account for 68% (N=310) of the cases in 
Maine in 2012. In Androscoggin, 124 (64%) cases were females and 69 (36%) were males. In Cumber-
land, 40 (34%) cases were females and 77 (66%) were males. This suggests mainly heterosexual trans-
mission patterns in Androscoggin county and primarily transmission among men who have sex with 
men in Cumberland county.    In Androscoggin county females, 65% of cases (N=81) are between ages 
20-29 and 83% of cases (N=103) are among whites. Among males, 55% of cases (N=38) are between 
ages 20-29 and 51% of cases (N=35) are among Black/African Americans. 
 
Federal CDC’s treatment guidelines for gonorrhea were updated in August 2012 due to increasing drug 
resistance. The new treatment guidance was disseminated to healthcare providers. Maine CDC respond-
ed to the increased incidence with press and public health promotion campaigns, especially targeting 
populations at risk in Androscoggin and Cumberland counties. These efforts include conducting public 
health partner education forums, disseminating updated treatment guidance (MMWR 61(31); 590-594) 
to healthcare providers and outreach efforts in bars, salons, healthcare clinics and social media sites.   
 
Appendix D 
Reported Cases of Gonorrhea, Maine, 2012 and Five Year 
Median
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Norovirus Outbreak at a Summer Camp – Maine, 2012 
Norovirus is one of the most common causes of gastrointestinal illness in people. Primary symptoms are 
acute  onset of vomiting and diarrhea that start  24 to 48 hours after swallowing the virus. Norovirus is 
highly contagious and is commonly spread in the following ways: 
 
 Eating food or drinking liquids that are contaminated with norovirus 
 Touching surfaces or objects contaminated with norovirus, and then placing hand in mouth 
 Having close contact with another person who has symptoms 
 
In July 2012, Maine CDC received a report of a cluster of gastrointestinal illness at a summer camp. The 
camp director reported a combination of nausea, vomiting, and diarrhea lasting about 24 hours affecting 
both campers and staff. The weeklong camp session ended early due to the amount of illness the camp 
was experiencing; campers and most staff were sent home. An outbreak team was formed which includ-
ed Infectious Disease Epidemiology and Health Inspections staff to investigate possible sources of expo-
sure and gather epidemiologic data related to the reported increase in gastrointestinal illness.  
 
Given the number of reported illness at the camp, the outbreak team decided to interview all staff mem-
bers to  characterize illness and determine if a food item was the cause of illness. Maine CDC epidemiol-
ogists interviewed 41 staff. Twenty-eight (68%) reported illness. Of those 28 ill staff members, symp-
toms reported were vomiting (83%), diarrhea (54%), headache (43%), abdominal cramps (39%) and fe-
ver (32%). The symptoms lasted about 24 hours. None of the staff members reported seeing a healthcare 
provider.  
 
The camp inspection revealed 3 critical and 9 non-critical violations. The violations included equipment 
and food contact surface and utensils not being clean, food being served and re-served, and inadequate 
food temperature. Records indicated that the previous years’ inspections had violations that were not 
addressed. The camp swimming pool inspection also revealed violations including poor records of sani-
tizer residual and pH testing results and low water turnover rates. 
 
One staff member and her partner submitted stool specimens that tested positive for norovirus 
genogroup II. No foods were considered to be statistically significant or the cause of illness. The illness 
was likely spread from person to person. No index source was identified as the cause of illness. Inter-
views with staff and illness logs showed that both staff and campers had gastrointestinal illness in the 
previous weeks that camp was in session. Limitations of the investigation included difficulty reaching all 
staff members after they were sent home, lack of information from campers, and varying camp illness 
logs due to a different person keeping records each week. The entire camp was cleaned and some of the 
violations were addressed. The Health Inspector allowed the camp to re-open for the remaining sessions.  
 
Key recommendations for the camp:  
 Address all violations from inspection reports 
 Fix identified issues with the pool including water circulation 
 Use proper environmental cleaning throughout the facility to stop the spread of illness 
 Keep standard, detailed, and complete nurse log information. 
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Increase in Pertussis – Maine, 2012 
In 2012, Maine experienced a statewide outbreak of pertussis. Cases of reported pertussis in Maine tri-
pled compared to 2011 cases.  
 
A total of 737 confirmed and probable pertussis cases were reported statewide in 2012 , compared to 
205 reported cases in 2011. The 2012 rate of pertussis in Maine was 55.5 cases per 100,000 persons, a 
significant increase from 2011 rate of 15.4 per 100,000 persons.  
 
Of the 737 cases of pertussis reported, the majority of cases (62.8%) occurred among children and ado-
lescents aged 7-19 years. Twenty-one (3%) cases were identified in children less than 6 months (Table 
1).  
 
 
 
 
 
 
 
 
 
 
 
 
Appendix F 
Table 1. Pertussis cases by age group -- 
Maine, 2012 
Age group # of cases Rate per 100,000 
< 6 mos 21 163.11 
6-11 mos 14 108.74 
1-6 yrs 108 128.49 
7-10 yrs 231 390.41 
11-19 yrs 232 155.65 
20-29 yrs 25 16.28 
30-39 yrs 41 27.63 
40-49 yrs 36 18.61 
50-59 yrs 12 5.55 
> 60 yrs 17 5.46 
All 737 55.49 
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Pertussis cases were identified among residents of all 16 counties (Table 2). Somerset county had the 
highest incidence with 196.1 cases per 100,000 persons compared to the state rate of 55.5 cases per 
100,000.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outbreaks of pertussis occurred in schools, daycares and child care activities. A weekly pertussis report 
was created to inform public health partners of the ongoing outbreak. The report was available on the 
Maine CDC website. 
 
Pertussis can be a serious illness for infants. Disease in young infants can be atypical and can progress 
rapidly to become severe and even fatal. Clinicians who care for infants should have a high index of sus-
picion for pertussis. Infants with illness compatible with pertussis should be tested, admitted to the hos-
pital, and treated immediately.  Maine distributed infant clinical treatment guidance based on guidance 
developed by the California Department of Public Health. This guidance is available online at         
www.mainepublichealth.gov.  
Maine CDC developed two pertussis outreach campaigns, one directed to providers to encourage recog-
nition of symptoms, proper testing and treatment. A second campaign was developed to target pregnant 
women and new mothers to encourage admission of vaccine for the mothers and other family members 
with close contact with a new baby. These materials can be ordered directly from the Maine CDC web-
site. 
Early treatment of pertussis is very important.  If treatment for pertussis is started early in the course of 
illness, symptoms may be lessened. Whenever possible, a nasopharyngeal (NP) swab or aspirate should 
be obtained from all persons with suspected pertussis.   
Healthcare providers are encouraged to promote the use of pertussis vaccines. There are two pertussis 
vaccines: DTaP for children  and Tdap for adolescents and adults.  Both vaccines contain pertussis anti-
gen in combination with tetanus and diphtheria. Tdap is recommended only for a single dose across all 
age groups.   
Table 2. Pertussis cases by county -- Maine, 2012 
County Count Rate per 100,000 
Androscoggin 65 60.52 
Aroostook 5 6.99 
Cumberland 225 79.67 
Franklin 1 3.25 
Hancock 44 80.62 
Kennebec 64 52.49 
Knox 14 35.26 
Lincoln 2 5.84 
Oxford 31 53.73 
Penobscot 67 43.57 
Piscataquis 24 137.78 
Sagadahoc 12 34.08 
Somerset 102 196.05 
Waldo 9 23.23 
Washington 2 6.13 
York 70 35.32 
Maine 737 55.49 
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Meaningful Use and Electronic Reporting Initiatives  – Maine, 2012 
Electronic laboratory reporting (ELR) has been promoted as a public health priority for the past several 
years and it’s inclusion as a Meaningful Use objective for public health serves as a catalyst to accelerate 
its adoption. The Meaningful Use objectives and measures for reportable laboratory results are as fol-
lows: 
 
Objective: 
Stage 1: Capability to submit electronic data on reportable (as required by state or local law) labor-
atory results to public health agencies and actual submission in accordance with applicable law 
and practice. 
Stage 2: Same as Stage 1. 
 
Measure: 
Stage 1: Performed at least one test of EHR technology’s capacity to provide electronic submission 
of reportable laboratory results to public health agencies and follow–up submission if the test is 
successful. 
Stage 2: Successful ongoing submission of electronic reportable laboratory results from Certified 
EHR Technology to public health agencies for the entire EHR reporting period as authorized. 
Note: ELR is a menu item (optional) for Stage 1 but is a core item (required) for Stage 2. 
 
The Maine Center for Disease Control and Prevention (Maine CDC) is partnering with HealthInfoNet 
(HIN), the State of Maine’s designated Health Information Exchange (HIE). A HIE is the transmission 
of healthcare-related data among hospitals, laboratories and public health agencies according to national 
standards. To meet requirements, HIN enables reliable and secure transfer of data among diverse sys-
tems and also facilitates access to and retrieval of data. Maine CDC dedicates resources to support im-
plementation of electronic laboratory reporting and works with clinical laboratories and HIN on the pro-
cess. 
 
There is a four-stage process for ELR implementation. Laboratories partnering with HIN to implement 
ELR will move through this process collaborating with HIN and Maine CDC: 
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2012 Tick Data Collected by the Maine Medical Center Research Institute 
Vector-Borne Disease Laboratory 
 
The Maine Medical Center Research Institute (MMCRI) Vector-Borne Disease Laboratory 
operates a free tick identification service as part of a program to establish the distribution of 
deer ticks (Ixodes scapularis) in the state. Ticks found on people and pets are submitted with 
information on where the tick(s) may have been acquired. Ticks are not tested for the presence 
of Lyme bacteria and MMCRI only accepts ticks from the state of Maine. 
 
It is important to note that this passive sampling could be influenced by a variety of extraneous 
factors (e.g. proximity to the laboratory, level of citizen concern about Lyme disease in an area, 
or whether or not a particular area is already widely known to have a deer tick presence). 
 
Number of Ticks Identified by County and Type, Maine, 2012 
 County 
Ixodes 
scapularis 
(Deer 
tick) 
Dermacentor 
variabilis 
(American 
dog tick) 
Ixodes 
cookei 
(Woodchuck 
tick) 
A. 
americanum 
(Lonestar 
tick) 
Androscoggin 25 5 0 0 
Aroostook 6 1 1 0 
Cumberland 159 53 1 1 
Franklin 8 10 0 0 
Hancock 133 10 4 1 
Kennebec 40 12 1 0 
Knox 14 6 0 0 
Lincoln 18 6 0 0 
Oxford 20 6 1 0 
Penobscot 114 7 1 0 
Piscataquis 8 0 1 0 
Sagadahoc 19 3 1 1 
Somerset 39 10 0 0 
Waldo 55 7 1 0 
Washington 7 1 0 0 
York 59 20 0 0 
Totals 724 157 12 3 
 
Why is it important to submit ticks for identification? 
It is important for a physician (or a pet's veterinarian) to know what species of tick was involved 
in a bite.  It is also important for surveillance purposes to know the type of tick and where ticks 
are found. 
 
What diseases are carried by which ticks? 
Ixodes scapularis (Deer tick) – Lyme disease, Anaplasmosis and Babesiosis 
Dermacentor variabilis (American dog tick) – Rocky Mountain Spotted Fever 
Ixodes cookei (Woodchuck tick) - Powassan  
Amblyoma americanum (Lonestar tick) - Ehrlichiosis 
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How are ticks removed? 
Remove ticks by grasping them with fine tweezers as near to the skin as possible and pull up 
gently but firmly.  A tick spoon is also effective. The barbed mouth parts may not let go easily.  It 
may take several minutes or more.  Do not handle ticks with bare hands.  
How are ticks submitted? 
Ticks should be sealed in a small, crushproof vial of 70% alcohol.  The vial should be padded 
with absorbent paper towel and sealed in a plastic bag, and mailed along with a completed 
submission form to:  
Vector-borne Disease Laboratory 
Maine Medical Center Research Institute 
75 John Roberts Rd., Suite 9B  
South Portland, ME 04106  
Print out the submission form from http://www.mmcri.org/lyme/, complete it, and mail it in with 
the specimen.  A report of the tick's identification will be sent to the submitter as soon as 
possible, usually within five days. A map may also be sent to assist in the identification of the 
site where tick exposure occurred. The public may address questions to the laboratory’s email 
address: ticklab@mmc.org or by calling 207-662-7142. 
 
 
Map Caption 
A map summarizing the number of Ixodes scapularis (deer tick) submitted per Minor Civil 
Division, 1989 through 2012. 
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  NOTIFIABLE CONDITIONS LIST   
  Maine Department of Health and Human Services  
    Center for Disease Control and Prevention 
  
           Conditions in BOLD must be reported immediately   All others must be reported in 48 hours 
 
 
Reportable Disease or Condition Laboratory Specimen Submission 
Acquired Immunodeficiency Syndrome (AIDS) 
Anthrax   
Arboviral Infection  
Babesiosis 
Botulism  
Brucellosis  
Campylobacteriosis 
Carbon Monoxide Poisoning, including 
- Clinical signs, symptoms or known 
exposure consistent with diagnosis of  
        carbon monoxide poisoning and/or: 
        a carboxyhemoglobin (COHb) level  
        >5% 
Chancroid 
Chlamydia 
Chickenpox (Varicella) 
Creutzfeldt-Jakob disease, <55 years of age 
Cryptosporidiosis 
Dengue 
Diphtheria  
E. coli, Shiga toxin-producing (STEC) disease  
   including E. coli: 0157:H7                                                                                                                                                                        
Ehrlichiosis 
Giardiasis 
Gonorrhea 
Haemophilus influenzae disease, invasive,    
   include all serotypes           
Hantavirus, pulmonary syndrome 
Hemolytic-uremic syndrome (post-diarrheal) 
Hepatitis A, B, C, D, E (acute) 
Hepatitis B (chronic, and/or perinatal) 
Hepatitis C (chronic) 
Hepatitis, acute (etiologic tests pending or  
  etiology unknown) 
Human Immunodeficiency Virus (HIV), 
   including: 
- Confirmed, positive antibody tests 
- Viral load tests, all results  
- CD4 lymphocyte counts, all results  
Influenza-associated pediatric death  
Influenza-like illness outbreaks 
Influenza A, Novel 
Legionellosis 
Leptospirosis 
Listeriosis  
Lyme Disease  
Malaria 
Measles   
Meningitis (bacterial) 
Meningococcal Invasive Disease  
Mumps  
Paralytic Shellfish Poisoning 
Pertussis  
Plague 
Poliomyelitis 
Psittacosis 
Q Fever  
Rabies (human and animal)  
Rabies Post-Exposure Prophylaxis 
Ricin Poisoning  
Rocky Mountain Spotted Fever 
Rubella (including congenital)  
Salmonellosis  
Severe Acute Respiratory Syndrome  
  (SARS) 
Shigellosis  
Smallpox  
Staphylococcus aureus, Methicillin-
  Resistant (MRSA) invasive,  
Staphylococcus aureus with     
  resistance (VRSA) or intermediate   
  resistance (VISA) to Vancomycin     
  isolated from any site 
Staphylococcal enterotoxin B  
Streptococcal invasive disease, Group A 
Streptococcal invasive disease, Group B 
Streptococcus pneumoniae, invasive          
  disease                                                         
Syphilis 
Tetanus  
Toxoplasmosis 
Trichinosis  
Tuberculosis (active and presumptive  
  cases)    
Tularemia  
Unusual or increased case incidence,  
  critical illness, unexplained death(s) 
  of any suspect infectious disease 
Vibrio species, including Cholera  
Viral Hemorrhagic Fever 
Venezuelan equine encephalitis 
Yellow Fever 
Yersiniosis 
Directors of laboratories are to submit cultures or clinical 
specimens for the following to the Maine Health and 
Environmental Testing Laboratory for confirmation, typing 
and/or antibiotic sensitivity:   
 
Acid-Fast Bacillus 
Bacillus anthracis 
Bordetella pertussis 
Brucella species 
Clostridium tetani 
Clostridium botulinum 
Corynebacterium diphtheriae 
Coxiella burnetii 
Escherichia coli, Shiga toxin-producing 
Haemophilus influenzae 
Human Immunodeficiency Virus 
Influenza virus, Novel 
Listeria monocytogenes 
Mumps virus 
Mycobacterium tuberculosis 
Neisseria meningitidis 
Rabies virus
Ricin Poisoning 
Rubella virus 
Rubeola virus 
Salmonella species 
SARS Coronavirus 
Shigella species 
Toxoplasma gondii 
Variola virus 
Vibrio species 
Yersinia pestis 
 
 
 
 
 
 
 
 
 
Who must report: Health Care Providers, Medical Laboratories, Health Care Facilities, 
Administrators, Health Officers, Veterinarians 
When to report: 
 Conditions in BOLD are reportable immediately by telephone on recognition or strong 
suspicion of disease 
 All others are reportable by telephone, fax, or mail within 48 hours of recognition or 
strong suspicion of disease 
What to report: 
Disease reports must include as much of the following as is known: 
 Disease or condition diagnosed or suspected 
 Patient’s name, date of birth, address, phone number, occupation and race 
 Diagnostic laboratory findings and dates of test relevant to the notifiable condition 
 Health care provider name, address and phone number 
 Name and phone number of person making the report 
 
Complete Rules for the Control of Notifiable Conditions at: 
http://www.maine.gov/dhhs/boh/ddc/epi/disease-reporting/index.shtml  
 
 
 
 April 4, 2008 
Disease Reporting 
24 Hours A Day 
7 Days A Week  
 
Telephone 
1-800-821-5821 
 
Fax 
1-800-293-7534 
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Penquis
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Central Maine
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Western Maine
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Downeast
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Mid Coast
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York
District 1
Cumberland
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Bangor
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Washington
York
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Map created by the Office of Public Health Emergency Preparedness
Updated November 2012
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Aroostook Band of Micmac Indians
Aroostook Micmac
Houlton Band of Maliseet Indians Health Dept
Houlton Maliseet
Penobscot Nation Health Dept
Maine Tribal Health Geographic Area
Passamaquoddy Tribe - Indian Township Health Center
Passamaquoddy Tribe -Pleasant Point Health
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Department of Health and Human Services 
Maine Center for Disease Control and Prevention 
State House Station #11 
Augusta, ME  04333-0011 
 
Paul R. LePage 
Governor 
 
Mary Mayhew 
Commissioner 
 
Dr. Sheila Pinette, DO 
Director, Maine Center for Disease Control and Prevention 
 
 
 
 
The Department of Health and Human Services (DHHS) does not discriminate on the 
basis of disability, race, color, creed, gender, age, sexual orientation, or national origin, in 
admission to, access to or operation of its programs, services, activities, or its hiring or 
employment practices.  This notice is provided as required by Title II of the Americans 
with Disabilities Act of 1990 and in accordance with the Civil Rights Acts of 1964 as 
amended.  Section 504 of the Rehabilitation Act of 1973 as amended, the Age 
Discrimination Act of 1975, Title IX of the Education Amendments of 1972 and the 
Maine Human Rights Act.  Questions, concerns, complaints, or requests for additional 
information regarding civil rights may be forwarded to the DHHS’ ADA 
Compliance/EEO Coordinator, State House Station #11, Augusta, Maine 04333, 207-
287-4289 (V) or 207-287-3488 (V), TTY: 800-606-0215.  Individuals who need auxiliary 
aids for effective communication in programs and services of DHHS are invited to make 
their needs and preferences known to the ADA Compliance/EEO Coordinator.  This 
notice is available in alternate formats, upon request. 
 
 
 
 
